var title_f8_0_8192="Propionibacterium shoulder";
var content_f8_0_8192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Propionibacterium shoulder infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bruising pattern along the surgical incision, often seen with Propionibacterium shoulder infections.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel J Sexton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8192=[""].join("\n");
var outline_f8_0_8192=null;
var title_f8_0_8193="Surgical treatment of thenar space abscess";
var content_f8_0_8193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Surgical treatment of thenar space abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep fascial space infections are surgical emergencies and there is no role for nonoperative treatment. The combined palmar and dorsal surgical approach to a thenar space abscess is illustrated here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8193=[""].join("\n");
var outline_f8_0_8193=null;
var title_f8_0_8194="Ulnar styloid";
var content_f8_0_8194=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fracture of the base of the ulnar styloid (anteroposterior radiograph)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extraarticular (Colles) distal radial fracture in frontal projection associated with a fracture of the base of the ulnar styloid which indicates disruption of the trianglar fibrocartilage complex (curved arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harris JH, Harris WH, Novelline RA. The Radiology of Emergency Medicine, 3rd ed. Williams &amp; Wilkins, Baltimore 1993. Copyright &copy; 1993 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8194=[""].join("\n");
var outline_f8_0_8194=null;
var title_f8_0_8195="Malignant antral ulcer UGI";
var content_f8_0_8195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant gastric ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast upper GI study demonstrates a large barium-filled ulcer crater (arrow) surrounded by edematous mucosa. The ulcer is extending from the stomach, across the pylorus and into the duodenum, features that are not seen with benign ulcers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8195=[""].join("\n");
var outline_f8_0_8195=null;
var title_f8_0_8196="Botryomycosis lesion";
var content_f8_0_8196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Botryomycosis lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lesion on the left knee.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Magauran, CE, Oethinger, M, Armstrong, WS. Photo Quiz: A marble under the skin. Clin Infect Dis 2008; 47:1579. Copyright &copy;2008 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8196=[""].join("\n");
var outline_f8_0_8196=null;
var title_f8_0_8197="Epiglottitis classic";
var content_f8_0_8197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Child with classic presentation of acute epiglottitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This four-year-old girl has epiglottitis caused by",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b.",
"    <br/>",
"    (A) She prefers to sit and appears anxious.",
"    <br/>",
"    (B) The child assumes the characteristic sniffing position to maximize the patency of her airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8197=[""].join("\n");
var outline_f8_0_8197=null;
var title_f8_0_8198="Muscular VSD multiple color";
var content_f8_0_8198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1184px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/62574/Muscular_VSD_mult_movie.mp4?title=Muscular+VSD+multiple+color\" style=\"width:496px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Muscular VSD multiple color",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With color flow mapping, three jets of flow can be seen crossing the intraventricular septum. The apical jets share a common origin of the left ventricular aspect of the septum but enter the right ventricle via separate orifices.",
"    <div class=\"footnotes\">",
"     LA: left atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; arrows: multiple muscular VSDs.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8198=[""].join("\n");
var outline_f8_0_8198=null;
var title_f8_0_8199="Corn - fifth toe";
var content_f8_0_8199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76048%7EDERM%2F56092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76048%7EDERM%2F56092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperkeratotic papule with a central \"core\" is present on the lateral fifth toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperkeratotic papule with a central \"core\" is present on the plantar surface near the base of the second toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8199=[""].join("\n");
var outline_f8_0_8199=null;
var title_f8_0_8200="Functional gallbladder disorder in adults";
var content_f8_0_8200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Functional gallbladder disorder in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8200/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8200/contributors\">",
"     Salam F Zakko, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8200/contributors\">",
"     Wisam F Zakko, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8200/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8200/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?8/0/8200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H152141066\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional gallbladder disorder is defined as biliary pain resulting from a primary gallbladder motility disturbance in the absence of gallstones, sludge, microlithiasis, or microcrystal disease. The diagnosis is considered in patients with typical biliary-type pain who have had other causes for the pain excluded. The prevalence of functional gallbladder disorder among patients with biliary-type pain and a normal transabdominal gallbladder ultrasound is up to 8 percent in men and 21 percent in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, functional gallbladder disorder has been referred to by various names, including gallbladder dyskinesia, gallbladder spasm, acalculous biliary disease, chronic acalculous cholecystitis, chronic acalculous gallbladder dysfunction, and cystic duct syndrome.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations, diagnosis, and treatment of patients with suspected functional gallbladder disorder. The approach to patients with other causes of biliary-type pain, including gallstones or suspected sphincter of Oddi dysfunction, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link\">",
"     \"Uncomplicated gallstone disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29126?source=see_link\">",
"     \"Treatment of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152141128\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of functional gallbladder disorder is unclear, but it is generally regarded as a motility disorder of the gallbladder. It may result from an initial metabolic disorder (ie, bile supersaturated with cholesterol) or a primary motility disorder in the absence, at least initially, of any abnormalities of bile composition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. It has been noted that patients with functional gallbladder disorder may have abnormal gastric emptying and colonic transit, suggesting a possible generalized gastrointestinal motility disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/6\">",
"     6",
"    </a>",
"    ]. The hypothesis that functional gallbladder disorder is related to abnormal gallbladder motility is the basis for measuring the gallbladder ejection fraction as part of the evaluation. (See",
"    <a class=\"local\" href=\"#H366143604\">",
"     'CCK-stimulated cholescintigraphy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152141043\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with functional gallbladder disorder present with biliary-type pain, also known as biliary colic. Their liver and pancreas blood tests are normal, no gallstones or gallbladder sludge are seen on imaging, and upper endoscopic examinations are normal. (See",
"    <a class=\"local\" href=\"#H234474439\">",
"     'Exclude gallstones'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366143384\">",
"    <span class=\"h2\">",
"     Biliary-type pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary-type pain is typically caused by cholelithiasis, sludge, microlithiasis, or microcrystal disease, but it can also be a manifestation of functional gallbladder disorder, sphincter of Oddi dysfunction, or common bile duct stones.",
"    <strong>",
"    </strong>",
"    Despite the name, biliary colic is usually constant and not colicky. The classic description is of an intense discomfort located in the right upper quadrant or epigastrium that may radiate to the back (particularly the right shoulder blade). The pain is often associated with diaphoresis, nausea, and vomiting. The pain plateaus in less than an hour, ranging from moderate to excruciating in severity. Once it has plateaued, the pain typically lasts at least 30 minutes and then slowly subsides over several hours, with the entire attack usually lasting less than six hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link&amp;anchor=H8995491#H8995491\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Biliary colic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While biliary-type pain often develops one to two hours after ingestion of a fatty meal, an association with meals is not universal, and in a significant proportion of patients the pain is nocturnal, with a peak occurrence around midnight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the pain has a characteristic pattern and timing for an individual patient. While the pain is recurrent, it occurs at variable intervals (not daily). After an attack, the physical examination is usually normal, with the possible exception of residual upper abdominal tenderness. While nonspecific dyspeptic symptoms, such as indigestion, abdominal bloating, and belching, may coexist in patients with biliary colic, they are not usually relieved by cholecystectomy. As a result, these symptoms are thought to be due to causes other than a gallbladder disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234473348\">",
"    <span class=\"h2\">",
"     Laboratory, imaging, and endoscopic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with functional gallbladder disorder have normal blood tests, including aminotransferases, bilirubin, alkaline",
"    <span class=\"nowrap\">",
"     phosphatase/gamma-glutamyl",
"    </span>",
"    transpeptidase, amylase, and lipase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, abdominal imaging is normal, with no evidence of gallstones, gallbladder sludge, or cholesterol polyps. Finally, patients have normal upper endoscopic examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152141027\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional gallbladder disorder is a diagnosis of exclusion in a patient with typical biliary-type pain. The first step in the evaluation of such patients is to exclude other causes for the patient's pain. If no other causes are identified, patients should undergo cholecystokinin (CCK)-stimulated cholescintigraphy to confirm the diagnosis. CCK-stimulated cholescintigraphy allows for calculation of the gallbladder ejection fraction (GBEF), which is low in patients with functional gallbladder disorder (&lt;40 percent) and helps predict which patients are likely to respond to cholecystectomy. (See",
"    <a class=\"local\" href=\"#H366143604\">",
"     'CCK-stimulated cholescintigraphy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H366143626\">",
"     'Patient selection for cholecystectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, while the GBEF is a component of consensus guidelines for diagnosing functional gallbladder disorder, many of the studies supporting the use of the GBEF for diagnosis are of poor methodologic quality and are not conclusive. Therefore, it is imperative that patients have a careful history obtained and that functional gallbladder disorder only be considered if typical biliary-type pain is present. The presence of typical biliary-type pain is the best predictor of a response to cholecystectomy in patients with a low GBEF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, some patients with normal gallbladder emptying and biliary-type pain also benefit from surgery. (See",
"    <a class=\"local\" href=\"#H366143626\">",
"     'Patient selection for cholecystectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234475935\">",
"    <span class=\"h2\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus guidelines (the Rome III criteria) have been developed to help diagnose functional gallbladder disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who fulfill these criteria should undergo an evaluation for functional gallbladder disorder, whereas patients who do not fulfill",
"    <strong>",
"     all",
"    </strong>",
"    of the criteria should be evaluated for alternative causes of their abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H6#H6\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Upper abdominal pain syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To fulfill the Rome III criteria for biliary-type pain, patients need to have pain that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is located in the epigastrium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right upper quadrant",
"     </li>",
"     <li>",
"      Is recurrent, but occurs at variable intervals (not daily)",
"     </li>",
"     <li>",
"      Lasts at least 30 minutes",
"     </li>",
"     <li>",
"      Builds up to a steady level",
"     </li>",
"     <li>",
"      Is severe enough to interrupt daily activities or lead to an emergency department visit",
"     </li>",
"     <li>",
"      Is not relieved by bowel movements, postural changes, or antacids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the criteria require that the gallbladder be present, that structural diseases that would explain the patient's symptoms are excluded, and that liver enzymes, pancreatic enzymes, and bilirubin are normal. Criteria that support the diagnosis, but are not required, include: (a) pain that is associated with nausea and vomiting, (b) pain that radiates to the back",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right subscapular region, and (c) pain that awakens the patient from sleep in the middle of the night.",
"   </p>",
"   <p>",
"    To make a definitive diagnosis, the Rome III criteria require a response to cholecystectomy, with no pain recurrence for at least 12 months. However, while this criterion helps confirm diagnosis, it is not helpful for determining which patients should undergo CCK-stimulated cholescintigraphy or are likely to respond to treatment with a cholecystectomy.",
"   </p>",
"   <p>",
"    The Rome III criteria help clinicians identify patients with typical biliary-type pain. We strongly believe that taking a careful history with a detailed description of the painful attacks is essential to identify patients with typical biliary attacks and that patients only be considered for further testing with CCK-stimulated cholescintigraphy if they have typical biliary-type pain and other possible causes of the pain have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234474294\">",
"    <span class=\"h2\">",
"     Exclude other diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with biliary-type pain, the evaluation begins with basic laboratory tests and a transabdominal ultrasound looking for gallstones or gallbladder sludge. If the transabdominal ultrasound is negative, it should be followed by EUS and bile microscopy to exclude small stones and microcrystal disease. If the evaluation for stones and microcrystal disease is negative, evaluation for other disorders in the differential diagnosis of biliary-type pain, including acid-peptic disease, ischemic heart disease, and functional gallbladder disorder should be pursued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234475595\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood tests should be obtained to look for evidence of liver disease, biliary obstruction, and pancreatitis. These tests include serum alanine aminotransferase, aspartate aminotransferase, bilirubin, alkaline",
"    <span class=\"nowrap\">",
"     phosphatase/gamma-glutamyl",
"    </span>",
"    transpeptidase, amylase, and lipase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234474439\">",
"    <span class=\"h3\">",
"     Exclude gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, a transabdominal ultrasound is the first imaging test obtained in patients with biliary-type pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Transabdominal ultrasound is noninvasive and does not expose patients to ionizing radiation. Patients should fast for eight hours prior to the ultrasound to allow for distension of the gallbladder, which permits better visualization of gallstones and sludge.",
"   </p>",
"   <p>",
"    Sludge is an ultrasound diagnosis of echogenic layering in the gallbladder that does not cast an acoustic shadow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86996 \" href=\"mobipreview.htm?13/41/13971\">",
"     image 1",
"    </a>",
"    ). Biliary sludge is composed of cholesterol microcrystals embedded in a mucous gel and pigment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients may also have a finding of \"gravel\" on ultrasound. Gravel is made up of small stones that may be beyond the resolution of ultrasound but that cast an acoustic shadow. The presence of sludge or gravel is as significant as the finding of stones in a patient with biliary type pain and is a clear indication for cholecystectomy in these patients. The same can be said about cholesterol polyps as these can detach and obstruct the cystic duct and the common bile duct, leading to biliary pain, cholecystitis, or pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link&amp;anchor=H58361345#H58361345\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Characteristics of stones on ultrasound'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13209?source=see_link\">",
"     \"Gallbladder polyps and cholesterolosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the initial transabdominal ultrasound is negative in a patient with typical biliary-type pain, a repeat examination should be obtained, with special attention being paid to commonly overlooked areas (eg, Hartmann's pouch or Phrygian cap, if present). If the repeat transabdominal ultrasound is still negative, additional testing may include an endoscopic ultrasound (EUS) to detect small stones that are beyond the resolution of transabdominal ultrasound. If EUS is negative, bile microscopy is performed to look for microlithiasis or microcrystal disease. We consider microlithiasis to be a synonym for microcrystal disease that can be diagnosed only with bile microscopy, although some authors refer to microlithiasis as small stones less than 3 mm in diameter that can be diagnosed with endoscopic ultrasound.",
"   </p>",
"   <p>",
"    A detailed approach to the diagnosis of gallstones is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link&amp;anchor=H7#H7\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234474521\">",
"    <span class=\"h3\">",
"     Exclude other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a negative evaluation for gallstones or sludge should be evaluated for other disorders in the differential diagnosis of biliary-type pain. This typically includes an evaluation for acid-peptic disease, consideration of functional dyspepsia, and evaluating for ischemic heart disease when indicated.",
"   </p>",
"   <p>",
"    Additional testing for disorders such as sphincter of Oddi dysfunction or chronic pancreatitis will depend upon the patient's history, symptoms, laboratory test findings, and imaging test results. Patients with sphincter of Oddi dysfunction often have elevated liver tests and a dilated bile duct. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link&amp;anchor=H58360586#H58360586\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59909115\">",
"    <span class=\"h4\">",
"     Acid-peptic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acid-peptic disease (peptic ulcer disease, gastroesophageal reflux disease) or functional dyspepsia may resemble patients with biliary disease. Patients with acid-peptic disease or functional dyspepsia may report burning pain in the epigastric area (dyspeptic pain) that occurs when fasting, two to four hours after a meal, or at night on an empty stomach.",
"   </p>",
"   <p>",
"    While dyspeptic pain may resemble biliary-type pain, dyspeptic pain is typically less severe and rarely results in a visit to the emergency room. In addition, dyspeptic pain is usually more prolonged and frequent than biliary-type pain, and often occurs on a daily basis. Unlike biliary-type pain, dyspeptic pain may be relieved by food or antacids. However, while a response to antacids is common in patients with peptic ulcer disease or acid reflux, the response is variable in patients with functional dyspepsia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H234474941\">",
"     'Functional dyspepsia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The approach to patients with dyspeptic pain depends upon the patient's age and associated symptoms. A trial of empiric antacid therapy is reasonable for younger patients with typical dyspeptic symptoms since upper endoscopy is generally of low yield in such patients. However, endoscopy is recommended for patients older than 45 years of age, those with \"alarm symptoms\" such as weight loss or anemia, and those who fail 10 to 14 days of empiric therapy. An upper endoscopy can be done during the same endoscopic session as EUS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link&amp;anchor=H59603517#H59603517\">",
"     \"Approach to the patient with dyspepsia\", section on 'Diagnostic strategies and initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234474941\">",
"    <span class=\"h4\">",
"     Functional dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like functional gallbladder disorder, functional dyspepsia is a diagnosis of exclusion, so prior to making either diagnosis, patients require a thorough evaluation. Once other disorders have been excluded, differentiating patients with functional gallbladder disorder from those with functional dyspepsia depends upon the character of the patient's symptoms. Unlike biliary pain, functional dyspepsia is usually described as a mild pain that is continuous or occurs daily and lasts for more than six hours. Functional dyspepsia is often associated with bloating and immediate worsening with meals. In patients with symptoms suggestive of functional dyspepsia, additional testing for functional gallbladder disorder is not indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H234474439\">",
"     'Exclude gallstones'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If patients have typical biliary-type pain, the disorders are differentiated based upon the results of CCK-stimulated cholescintigraphy, with a low gallbladder ejection fraction (&lt;40 percent) making a diagnosis of functional gallbladder disorder more likely. (See",
"    <a class=\"local\" href=\"#H366143604\">",
"     'CCK-stimulated cholescintigraphy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H57284154\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59909135\">",
"    <span class=\"h4\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery disease, particularly inferior wall ischemia, may present as upper abdominal discomfort. Typically, this type of discomfort differs from biliary-type pain in that it is effort induced, radiates to the chest or left shoulder, and has a sudden onset. Clinicians should have a low threshold for initiating a cardiac evaluation, particularly in patients with risk factors for coronary artery disease or with other symptoms suggestive of cardiac disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366143604\">",
"    <span class=\"h2\">",
"     CCK-stimulated cholescintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCK-stimulated cholescintigraphy is used to estimate the gallbladder ejection fraction (GBEF). Patients with a GBEF of less than 35 to 40 percent are considered to have abnormal gallbladder motility and are more likely to respond to cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. CCK-stimulated cholescintigraphy should only be performed in patients with typical biliary symptoms. It should",
"    <strong>",
"     not",
"    </strong>",
"    be ordered for atypical symptoms such as bloating, fullness, or dyspeptic symptoms, as these patients are unlikely to respond to surgery even in the presence of a low GBEF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H366143626\">",
"     'Patient selection for cholecystectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following an overnight fast, 99mTc-diisopropyl-iminodiacetic acid (DISIDA) or 99mTc-hepatic iminodiacetic acid (HIDA) is given as an intravenous bolus. The radiolabeled tracer is excreted in the bile, and if the cystic duct is patent, it will flow into the gallbladder. After 45 to 90 minutes, baseline radioactivity from the region of the gallbladder is measured. When the radioactivity is maximal from the gallbladder and is minimal from the liver, an infusion of CCK is started to stimulate gallbladder contraction, which leads to expulsion of the radiolabeled tracer. CCK-stimulated cholescintigraphy should be performed with a slow infusion of CCK (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8435?source=see_link\">",
"     sincalide",
"    </a>",
"    0.02",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    given over 30 to 60 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/16\">",
"     16",
"    </a>",
"    ]. Rapid administration of CCK (over two to three minutes) is associated with cramping, patient discomfort, and highly variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/14\">",
"     14",
"    </a>",
"    ]. Slower infusion rates (over 30 to 60 minutes) lead to less inter- and intra-subject variability and an overall increase in mean gallbladder ejection fraction compared with rapid infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Variability in CCK administration techniques may account for some of the differences seen in studies examining the ability of the GBEF to predict a response to cholecystectomy (See",
"    <a class=\"local\" href=\"#H366143626\">",
"     'Patient selection for cholecystectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following CCK infusion, the radioactivity in the region of the gallbladder is again measured and subtracted from the baseline activity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87708 \" href=\"mobipreview.htm?42/28/43469\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The GBEF is then calculated using the formula:",
"   </p>",
"   <p>",
"    GBEF = (baseline activity &ndash; activity after CCK",
"    <span class=\"nowrap\">",
"     infusion)/baseline",
"    </span>",
"    activity",
"   </p>",
"   <p>",
"    Multiple medications and medical conditions other than functional gallbladder disorder are associated with decreased gallbladder emptying and should be kept in mind when interpreting CCK-stimulated cholescintigraphy results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/10,20,21\">",
"     10,20,21",
"    </a>",
"    ]. False-positive results can be seen with diabetes, celiac disease, obesity, cirrhosis, and several medications, including calcium channel blockers, oral",
"    <span class=\"nowrap\">",
"     contraceptives/progesterone,",
"    </span>",
"    histamine-2 receptor antagonists, opiates, benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A systematic review attempted to evaluate the usefulness of GBEF for determining which patients with suspected functional gallbladder disorder are likely to respond to cholecystectomy (thus making a diagnosis of functional gallbladder disorder more likely). It included 23 studies with 1718 patients with suspected functional gallbladder disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/22\">",
"     22",
"    </a>",
"    ]. Nineteen of the studies concluded that calculation of a GBEF was useful in predicting a response to cholecystectomy in patients with suspected functional gallbladder disorder. However, the authors noted that all of the studies were of poor methodologic quality, which precluded a meta-analysis. All but three of the studies were retrospective case series, only one was randomized, and no study was adequately blinded.",
"   </p>",
"   <p>",
"    As an example, one study that suggested GBEF is useful for predicting a response to cholecystectomy retrospectively analyzed 345 patients with biliary-type pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/23\">",
"     23",
"    </a>",
"    ]; 195 patients had a low GBEF (&lt;35 percent) and 150 had a normal GBEF (&ge;35 percent). Among those with a low GBEF, 110 of 113 patients (97 percent) treated with surgery had symptom improvement, compared with 13 of 82 (16 percent) who were managed medically for non-gallbladder disease. Conversely, patients with normal GBEFs did well with medical management for non-gallbladder disease, with 130 of 139 patients (94 percent) reporting improvement. Finally, patients with normal GBEFs who were referred for surgery also did well (10 of 11 had symptom improvement), though it is not clear from the study what lead to the patients being referred for surgery. Thus, this study suggests that surgical therapy is appropriate for patients with a low GBEF and that medical therapy is appropriate for those with a normal GBEF. However, the study is limited by the fact that it is retrospective, leading to potential biases regarding which patients were referred for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169802769\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary considerations in the differential diagnosis of functional gallbladder disorder are gallstones and gallbladder sludge, which are more common causes of biliary-type pain. Gallstones and sludge are typically identified on transabdominal ultrasound, though in some cases endoscopic ultrasound or biliary microscopy may be required. Cholesterol polyps are another cause for biliary pain that can be diagnosed with ultrasound. (See",
"    <a class=\"local\" href=\"#H234474439\">",
"     'Exclude gallstones'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13209?source=see_link\">",
"     \"Gallbladder polyps and cholesterolosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other considerations in the differential diagnosis include sphincter of Oddi dysfunction and non-biliary causes of abdominal pain, such as functional dyspepsia. (See",
"    <a class=\"local\" href=\"#H234474521\">",
"     'Exclude other disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57284154\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholecystectomy is the treatment for functional gallbladder disorder. Patients are candidates for cholecystectomy if they fulfill the clinical criteria for functional gallbladder disorder, if alternative explanations for their symptoms have been excluded, and if their gallbladder ejection fraction (GBEF) is reduced (&lt;40 percent). Patients who develop pain during cholecystokinin infusion may be particularly likely to respond well to cholecystectomy, though it is important that the cholecystokinin be administered properly, as rapid administration could result in cramping that may be confused with the patient's biliary-type pain. Alternative therapies, such as bile acid composition modifiers, promotility agents, and anti-inflammatory drugs, have not been adequately studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36489?source=see_link\">",
"     \"Open cholecystectomy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H366143604\">",
"     'CCK-stimulated cholescintigraphy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The benefit of cholecystectomy over nonsurgical management was demonstrated in a meta-analysis that included 10 studies with a total of 615 patients with right upper quadrant pain, no gallstones, and a positive cholecystokinin (CCK)-stimulated hepatic iminodiacetic acid (HIDA) scan. It found that cholecystectomy was more likely than medical therapy to achieve complete symptom relief in patients with a low GBEF (odds ratio 16.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the included studies had numerous limitations, including lack of blinding, nonrandomized designs, variable lengths of follow-up, non-standardized protocols for determining the GBEF, non-standardized methods of assessing clinical outcomes, and poor follow-up of dropouts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366143626\">",
"    <span class=\"h2\">",
"     Patient selection for cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with functional gallbladder disorder are candidates for cholecystectomy if they have typical biliary-type pain and a low GBEF (&lt;40 percent). While studies suggest that such patients are likely to benefit from cholecystectomy, most of the studies showing an association of a low GBEF with improved outcomes are retrospective, and GBEF has not conclusively been proven to be a reliable indicator of clinical outcome. However, while imperfect, it is the most studied predictor of whether a patient will respond to cholecystectomy. (See",
"    <a class=\"local\" href=\"#H366143604\">",
"     'CCK-stimulated cholescintigraphy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is uncontrolled observational evidence that the recreation of a patient's typical biliary-type pain during CCK infusion (CCK provocation) may predict a response to cholecystectomy, regardless of GBEF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/11,26-28\">",
"     11,26-28",
"    </a>",
"    ]. In a series of 42 patients undergoing cholecystectomy for biliary-type pain and no gallstones, 17 had a GBEF of &lt;35 percent and 25 had a GBEF of &ge;35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8200/abstract/27\">",
"     27",
"    </a>",
"    ]. All of the patients had recreation of their pain during CCK infusion. Despite the normal GBEF in 25 patients, all 42 patients had symptom resolution following cholecystectomy, and only one patient had recurrent symptoms after a mean follow-up of 19 months.",
"   </p>",
"   <p>",
"    We do not generally base surgical decisions based upon CCK provocation of abdominal pain because of variability in describing pain and the subjective nature of this test. However, the recreation of typical biliary-type pain during CCK-stimulated cholescintigraphy may be supportive of the diagnosis, and rarely we will refer a patient with CCK-provoked biliary-type pain and a normal GBEF for cholecystectomy, provided treatments for other disorders (eg, acid suppressive therapy) have failed. However, we must stress that many times the infusion of CCK will lead to abdominal cramping, especially in the case of rapid infusion. Cramping due to the CCK infusion must not be confused with recreation of the patient's biliary-type pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152141178\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional gallbladder disorder is a diagnosis that is considered in patients with typical biliary-type pain who do not have gallstones or gallbladder sludge. It is a diagnosis of exclusion, and the symptoms associated with functional gallbladder disorder may also be seen in patients with various disorders, including gallstone disease, peptic ulcer disease, ischemic heart disease, and functional dyspepsia. (See",
"      <a class=\"local\" href=\"#H152141043\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H169802769\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To make a diagnosis of functional gallbladder disorder, specific clinical criteria should be met, and other causes for the patient's pain need to be ruled out. Cholecystokinin-stimulated cholescintigraphy is then performed to identify patients who may respond to cholecystectomy. (See",
"      <a class=\"local\" href=\"#H152141027\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our general approach to patients who meet criteria for typical biliary-type pain is as follows (see",
"      <a class=\"local\" href=\"#H234475935\">",
"       'Clinical criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obtain liver and pancreas blood tests to look for evidence of biliary obstruction or pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link\">",
"       \"Approach to the patient with suspected choledocholithiasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exclude gallstones, sludge, cholesterol polyps, and microcrystal disease. (See",
"      <a class=\"local\" href=\"#H234474439\">",
"       'Exclude gallstones'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If the evaluation for these biliary sources of pain is negative, consider other disorders in the differential diagnosis of biliary-type pain. This typically includes evaluating for acid-peptic disease, functional dyspepsia, and ischemic heart disease when indicated. Additional testing for disorders such as sphincter of Oddi dysfunction or chronic pancreatitis will depend upon the patient's history, symptoms, laboratory test findings, and imaging test results. (See",
"      <a class=\"local\" href=\"#H234474294\">",
"       'Exclude other diagnoses'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link&amp;anchor=H58360586#H58360586\">",
"       \"Uncomplicated gallstone disease in adults\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If other disorders are excluded in a patient with typical biliary-type pain, perform CCK-stimulated cholescintigraphy to calculate the gallbladder ejection fraction. Patients with atypical symptoms such as bloating, fullness, or dyspeptic symptoms, are generally treated for functional dyspepsia and should not undergo CCK-stimulated cholescintigraphy. (See",
"      <a class=\"local\" href=\"#H366143604\">",
"       'CCK-stimulated cholescintigraphy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=see_link\">",
"       \"Functional dyspepsia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the gallbladder ejection fraction is &lt;40 percent and there are no other conditions associated with reduced gallbladder emptying, the diagnosis of functional gallbladder disorder is possible, and treatment for functional gallbladder disorder is reasonable. The diagnosis can only be confirmed if the patient responds to treatment. (See",
"      <a class=\"local\" href=\"#H57284154\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that patients with suspected functional gallbladder disorder following an appropriate evaluation be treated with cholecystectomy rather than medical management (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with atypical symptoms or a normal gallbladder ejection fraction are less likely to respond to treatment and should be reassessed for alternative causes of their symptoms. We will rarely consider cholecystectomy in patients with typical biliary-type pain and a normal gallbladder ejection fraction, provided no other likely diagnoses have been identified, empiric treatments for other disorders (eg, acid suppressive therapy) have failed, and the pain is reproduced with a properly administered CCK infusion. (See",
"      <a class=\"local\" href=\"#H366143626\">",
"       'Patient selection for cholecystectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/1\">",
"      Prevalence of gallstone disease in an Italian adult female population. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO). Am J Epidemiol 1984; 119:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/2\">",
"      Barbara L, Sama C, Morselli Labate AM, et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology 1987; 7:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/3\">",
"      The epidemiology of gallstone disease in Rome, Italy. Part I. Prevalence data in men. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO). Hepatology 1988; 8:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/4\">",
"      Behar J, Corazziari E, Guelrud M, et al. Functional gallbladder and sphincter of oddi disorders. Gastroenterology 2006; 130:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/5\">",
"      Amaral J, Xiao ZL, Chen Q, et al. Gallbladder muscle dysfunction in patients with chronic acalculous disease. Gastroenterology 2001; 120:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/6\">",
"      Penning C, Gielkens HA, Delemarre JB, et al. Gall bladder emptying in severe idiopathic constipation. Gut 1999; 45:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/7\">",
"      LUND J. Surgical indications in cholelithiasis: prophylactic choleithiasis: prophylactic cholecystectomy elucidated on the basis of long-term follow up on 526 nonoperated cases. Ann Surg 1960; 151:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/8\">",
"      Rigas B, Torosis J, McDougall CJ, et al. The circadian rhythm of biliary colic. J Clin Gastroenterol 1990; 12:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/9\">",
"      Kraag N, Thijs C, Knipschild P. Dyspepsia--how noisy are gallstones? A meta-analysis of epidemiologic studies of biliary pain, dyspeptic symptoms, and food intolerance. Scand J Gastroenterol 1995; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/10\">",
"      Hansel SL, DiBaise JK. Functional gallbladder disorder: gallbladder dyskinesia. Gastroenterol Clin North Am 2010; 39:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/11\">",
"      Carr JA, Walls J, Bryan LJ, Snider DL. The treatment of gallbladder dyskinesia based upon symptoms: results of a 2-year, prospective, nonrandomized, concurrent cohort study. Surg Laparosc Endosc Percutan Tech 2009; 19:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/12\">",
"      Cooperberg PL, Burhenne HJ. Real-time ultrasonography. Diagnostic technique of choice in calculous gallbladder disease. N Engl J Med 1980; 302:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/13\">",
"      Lee SP, Nicholls JF. Nature and composition of biliary sludge. Gastroenterology 1986; 90:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/14\">",
"      Ziessman HA. Cholecystokinin cholescintigraphy: victim of its own success? J Nucl Med 1999; 40:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/15\">",
"      Bingener J, Richards ML, Schwesinger WH, Sirinek KR. Laparoscopic cholecystectomy for biliary dyskinesia: correlation of preoperative cholecystokinin cholescintigraphy results with postoperative outcome. Surg Endosc 2004; 18:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/16\">",
"      DiBaise JK, Richmond BK, Ziessman HA, et al. Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. Clin Nucl Med 2012; 37:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/17\">",
"      Ziessman HA. Functional hepatobiliary disease: chronic acalculous gallbladder and chronic acalculous biliary disease. Semin Nucl Med 2006; 36:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/18\">",
"      Sarva RP, Shreiner DP, Van Thiel D, Yingvorapant N. Gallbladder function: methods for measuring filling and emptying. J Nucl Med 1985; 26:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/19\">",
"      Hopman WP, Jansen JB, Rosenbusch G, Lamers CB. Gall bladder contraction induced by cholecystokinin: bolus injection or infusion? Br Med J (Clin Res Ed) 1986; 292:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/20\">",
"      Vassiliou MC, Laycock WS. Biliary dyskinesia. Surg Clin North Am 2008; 88:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/21\">",
"      Francis G, Baillie J. Gallbladder dyskinesia: fact or fiction? Curr Gastroenterol Rep 2011; 13:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/22\">",
"      DiBaise JK, Oleynikov D. Does gallbladder ejection fraction predict outcome after cholecystectomy for suspected chronic acalculous gallbladder dysfunction? A systematic review. Am J Gastroenterol 2003; 98:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/23\">",
"      Fink-Bennett D, DeRidder P, Kolozsi WZ, et al. Cholecystokinin cholescintigraphy: detection of abnormal gallbladder motor function in patients with chronic acalculous gallbladder disease. J Nucl Med 1991; 32:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/24\">",
"      Hansel SL, Dibaise JK. Gallbladder dyskinesia. Curr Treat Options Gastroenterol 2008; 11:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/25\">",
"      Mahid SS, Jafri NS, Brangers BC, et al. Meta-analysis of cholecystectomy in symptomatic patients with positive hepatobiliary iminodiacetic acid scan results without gallstones. Arch Surg 2009; 144:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/26\">",
"      Rastogi A, Slivka A, Moser AJ, Wald A. Controversies concerning pathophysiology and management of acalculous biliary-type abdominal pain. Dig Dis Sci 2005; 50:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/27\">",
"      Morris-Stiff G, Falk G, Kraynak L, Rosenblatt S. The cholecystokin provocation HIDA test: recreation of symptoms is superior to ejection fraction in predicting medium-term outcomes. J Gastrointest Surg 2011; 15:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8200/abstract/28\">",
"      DuCoin C, Faber R, Ilagan M, et al. Normokinetic biliary dyskinesia: a novel diagnosis. Surg Endosc 2012; 26:3088.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16725 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8200=[""].join("\n");
var outline_f8_0_8200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H152141178\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152141066\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152141128\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152141043\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366143384\">",
"      Biliary-type pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234473348\">",
"      Laboratory, imaging, and endoscopic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152141027\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234475935\">",
"      Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234474294\">",
"      Exclude other diagnoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234475595\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234474439\">",
"      - Exclude gallstones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234474521\">",
"      - Exclude other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H59909115\">",
"      Acid-peptic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H234474941\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H59909135\">",
"      Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366143604\">",
"      CCK-stimulated cholescintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H169802769\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57284154\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366143626\">",
"      Patient selection for cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152141178\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/16725\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16725|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/41/13971\" title=\"diagnostic image 1\">",
"      Ultrasound gallbladder sludge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/28/43469\" title=\"diagnostic image 2\">",
"      Quantitative HIDA scan decreased ejection fraction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13209?source=related_link\">",
"      Gallbladder polyps and cholesterolosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36489?source=related_link\">",
"      Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29126?source=related_link\">",
"      Treatment of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_0_8201="Approach to hypoglycemia in infants and children";
var content_f8_0_8201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to hypoglycemia in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8201/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8201/contributors\">",
"     Agneta Sunehag, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8201/contributors\">",
"     Morey W Haymond, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8201/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8201/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?8/0/8201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In healthy individuals, maintenance of a normal plasma glucose concentration depends upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A normal endocrine system for integrating and modulating substrate mobilization, interconversion, and utilization",
"     </li>",
"     <li>",
"      Functionally intact enzymes for glycogenolysis, glycogen synthesis, glycolysis, gluconeogenesis, and utilization of other metabolic fuels for oxidation and storage",
"     </li>",
"     <li>",
"      An adequate supply of endogenous fat, glycogen, and potential gluconeogenic substrates (eg, amino acids, glycerol, and lactate)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adults are capable of maintaining a near-normal blood glucose concentration, even when totally deprived of calories for weeks or, in the case of obese subjects, months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, healthy neonates and young children are unable to maintain normal plasma glucose concentrations after even a short fast (24 to 36 hours) and exhibit a progressive decline in plasma glucose concentration to hypoglycemic values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities in hormone secretion, substrate interconversion, and mobilization of metabolic fuels contribute to abnormalities in glucose production and utilization that ultimately result in hypoglycemia in children. The appropriate evaluation and treatment of the child with hypoglycemia require an understanding of the factors that regulate glucose metabolism and the unique aspects of glucose metabolism in infants and young children.",
"   </p>",
"   <p>",
"    Glucose homeostasis and the diagnostic approach to hypoglycemia in infants and children will be discussed here. The causes of hypoglycemia and hypoglycemia in neonates are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLUCOSE HOMEOSTASIS IN NORMAL INFANTS AND CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout gestation, maternal glucose is transported across the placenta to meet a substantial proportion of the energy needs of the fetus. In animals, the activity of one or more important rate-limiting enzymes of gluconeogenesis (pyruvate carboxylase, phosphoenol-pyruvate carboxykinase, glucose-6-phosphatase, and fructose 1,6 diphosphatase) is absent or very low in the fetus, does not increase until the perinatal period, and reaches adult levels only after several hours to days of extrauterine life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/4\">",
"     4",
"    </a>",
"    ]. In keeping with these findings, there is no evidence of fetal glucose production at birth in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/5\">",
"     5",
"    </a>",
"    ]. However, hepatic glucose production and gluconeogenesis are well established within hours of birth, even in very premature infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/6\">",
"     6",
"    </a>",
"    ]. The enzymes necessary for glycogen synthesis and glycogenolysis are present in the fetal liver long before the accumulation of glycogen can be demonstrated. It is only during the last three to four weeks of gestation in humans that hepatic glycogen stores increase to reach values at birth seen only in children with glycogen storage diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interruption of placental blood flow as a result of the clamping of the umbilical cord at birth requires the infant to utilize his or her own endogenous substrates and challenges the newborn with his or her first fast. With the clamping of the cord, there is an immediate release of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/7\">",
"     7",
"    </a>",
"    ]. However, despite the glucagon surge, plasma glucose decreases over the first two hours of life. This is accompanied by a decrease in insulin and an increase in free fatty acids (FFAs) and ketone bodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/8\">",
"     8",
"    </a>",
"    ]. By four to six hours of life, in most infants, the plasma glucose concentration is stabilized or is increasing. It is presumed that much of the initial glucose production is from the mobilization of hepatic glycogen, since hepatic glycogen content decreases during the first several days of extrauterine life. This release of hepatic glycogen facilitates a smooth transition from the continuously fed (intrauterine) to the fasted or relatively fasted condition of the first hours to days of extrauterine life. However, hepatic glycogen content is limited, and within hours of birth gluconeogenesis must meet an ever-increasing proportion of endogenous glucose production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fatty acid mobilization and metabolism play a crucial role in the maintenance of glucose homeostasis in infants and children. Plasma FFAs and ketone bodies can be used by a variety of body tissues and, thus, decrease the demands of these tissues for glucose as an energy source. The brain is unique in that it uses glucose at a rate 20 times that of other body tissues (per gram) and cannot use FFAs directly since they are not transported across the blood-brain barrier. However, ketone bodies (eg, &szlig;-hydroxybutyric acid and acetoacetic acid) are transported across the blood-brain barrier, and their metabolism by the brain can partially supplant the need for glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/1\">",
"     1",
"    </a>",
"    ]. The metabolic response to fasting in children is similar to that in adults. However, children have a more rapid decline in plasma glucose concentration and a more rapid increase in the plasma concentration of ketone bodies than do adults. These findings suggest the relative increase in the glucose requirement in children may result in an acceleration of the normal adaptive mechanism(s) of fasting observed in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the first 8 to 10 years of life, the rate of glucose utilization (and production) increases, followed by a plateau during the next five to seven years, after which the normal adult rate (833 to 944",
"    <span class=\"nowrap\">",
"     micromol/min",
"    </span>",
"    [150 to 170",
"    <span class=\"nowrap\">",
"     mg/min])",
"    </span>",
"    is achieved (",
"    <a class=\"graphic graphic_figure graphicRef64790 \" href=\"mobipreview.htm?7/49/7966\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/9\">",
"     9",
"    </a>",
"    ]. Studies utilizing isotopically-labeled glucose indicate that, by weight, rates of glucose flux (production and utilization) in adults are approximately 11 to 13",
"    <span class=\"nowrap\">",
"     micromol/kg",
"    </span>",
"    per min (2 to 2.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min) in the overnight postabsorptive state (14-hour fast) and decrease to 9.8",
"    <span class=\"nowrap\">",
"     micromol/kg",
"    </span>",
"    per min (1.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min) by 30 hours of fasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/10\">",
"     10",
"    </a>",
"    ]. The rate of glucose flux in infants and children after 4 to 14 hours of fasting is nearly three times higher (35",
"    <span class=\"nowrap\">",
"     micromol/kg",
"    </span>",
"    per min [6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min]) than that of adults, and decreases to 23",
"    <span class=\"nowrap\">",
"     micromol/kg",
"    </span>",
"    per min (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min) after a 30- to 40-hour fast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the premature and term infant, more than 90 percent of the glucose is utilized by the brain. Over time, this value decreases to approximately 40 percent of glucose turnover in overnight-fasted adults (",
"    <a class=\"graphic graphic_figure graphicRef76157 \" href=\"mobipreview.htm?13/21/13662\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/9\">",
"     9",
"    </a>",
"    ]. The higher rates of glucose turnover per kilogram of body weight in infants and children when compared with adults are consistent with the relatively higher proportion of brain mass to body size, which places infants and children at higher risk of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary orchestration of substrate mobilization (or storage) and utilization is the result of classical actions of hormones (eg, insulin,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    , catecholamines, cortisol and growth hormone), although more subtle interactions of other factors (eg, cytokines, neuronal input, glucagon-like peptide 1 (GLP1) post-receptor activation mechanism) are now being recognized. Insulin secretion plays a central role in glucose homeostasis and is affected by a number of factors, the most important of which is the plasma glucose concentration. A more detailed description of the secretion and actions of insulin is presented separately. However, we provide a brief description here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41702?source=see_link\">",
"     \"Insulin secretion and pancreatic beta-cell function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25511?source=see_link\">",
"     \"Insulin action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the plasma glucose concentration increases after a meal in normal individuals, glucose is transported into the pancreatic beta-cell via the GLUT2 transporter, is phosphorylated by glucokinase, and metabolized via the glycolytic pathway. This results in an increase in the",
"    <span class=\"nowrap\">",
"     ATP/ADP",
"    </span>",
"    ratio, which closes the K",
"    <sub>",
"     ATP",
"    </sub>",
"    channels, depolarizes the cell membrane, opening the Ca2+ channels, resulting in fusion of the insulin granule with the plasma membrane causing insulin secretion. Conversely, a decrease in blood glucose concentration results in decreased glucose metabolism in the beta-cell, which leads to a reduced",
"    <span class=\"nowrap\">",
"     ATP/ADP",
"    </span>",
"    ratio, opening of the K",
"    <sub>",
"     ATP",
"    </sub>",
"    channels, hyperpolarization of the cell membrane, and closure of Ca2+ channels, thus blocking Ca2+ influx and reducing insulin secretion. Fundamental problems in these processes can lead to profound hypoglycemia in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During controlled insulin-induced hypoglycemia, children typically mount a greater counterregulatory hormone response (eg, with cortisol, epinephrine, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    ) than do adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, with repeated episodes of hypoglycemia, secretion of counterregulatory hormones wanes, leading to what is called \"hypoglycemic unawareness\" in an individual with diabetes. In the absence of classical symptoms of hypoglycemia, perhaps as a result of this process, the diagnosis of hypoglycemia can be missed in some children for months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION OF HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise definition of hypoglycemia in infants and children continues to be controversial. Knowing the conditions preceding the collection of blood for a quantitative glucose determination is critical to its interpretation. As an example, the normal distribution of glucose values following a meal, an overnight fast, or a 30- to 40-hour fast, will be strikingly different. Creating different definitions of hypoglycemia based upon the child's age, gestation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight (small, average, or large for gestational age), feeding or fasting will not resolve this controversy. The overall goal of identifying children with hypoglycemia is to protect their central nervous systems from irreparable damage as a result of severe, prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeated episodes of hypoglycemia. There is no a priori reason that a premature or low-birth-weight infant should tolerate a low glucose concentration better than an older child; in fact, quite the opposite might be argued.",
"   </p>",
"   <p>",
"    For diagnostic purposes, we define hypoglycemia as a plasma glucose value of &le;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.22 mM) regardless of age. As discussed above, the physiologic nadir of the plasma glucose occurs in the first two to four hours of life, but normally increases to values &gt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    by six hours of life. Other than this unique circumstance, a documented plasma glucose concentration of &le;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.22 mM) should trigger a formal evaluation. However, this concentration should not be construed as ideal or necessarily safe over time, and should only be used in identifying an individual at risk for",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diagnosing hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body maintains a delicate balance between the rate at which glucose is produced or enters the circulation (appearance rate) and the rate at which it is utilized (disappearance rate). When the rate of appearance of glucose into the plasma exceeds the rate of disappearance, the plasma glucose concentration increases. Conversely, when the rate of disappearance is greater than the rate of appearance, the plasma glucose concentration decreases. In many hypoglycemic conditions, the understanding of glucose kinetics is insufficient to assign a clear cause (eg, increased utilization or decreased production). In other conditions, a combination of decreased production and increased utilization is thought to contribute to the development of hypoglycemia. Specific causes of hypoglycemia in infants and children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants, the signs of hypoglycemia are frequently nonspecific, but may include the signs of severe neuroglycopenia discussed below. The signs of hypoglycemia include irritability, jitteriness, feeding problems, lethargy, cyanosis, tachypnea, and hypothermia. These signs are not specific for hypoglycemia and may be early manifestations of a number of other disorders, including septicemia, congenital heart disease, ventricular hemorrhage, and respiratory distress syndrome. Infants are at greatest risk for hypoglycemia during the first few days of life. Neonatal hypoglycemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children and adults, the symptoms of hypoglycemia can be divided into two categories: those caused by the autonomic response to hypoglycemia and those caused by neuroglycopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autonomic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early manifestations of hypoglycemia are caused by the autonomic response to hypoglycemia and include sweating, weakness, tachycardia, tremor, and feelings of nervousness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hunger. These symptoms and signs usually occur at higher blood glucose concentrations (between 40 and 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.2 and 3.9 mM]) than the neuroglycopenic signs and symptoms, and may function as a \"warning system.\" However, with repeated or prolonged episodes of hypoglycemia, the threshold for autonomic symptoms decreases to that for neuroglycopenic symptoms. This can result in the appearance of severe symptoms of hypoglycemia with little or no warning: \"hypoglycemic unawareness.\" (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Glucose homeostasis in normal infants and children'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuroglycopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of neuroglycopenia occur with prolonged hypoglycemia and at lower plasma concentrations of glucose (approximately 10 to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.5 to 2.8 mM]). These include lethargy, irritability, confusion, uncharacteristic behavior, hypothermia, and, in extreme hypoglycemia, seizure and coma. Severe and repeated episodes of hypoglycemia can result in permanent central nervous system damage, and occasionally, death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMMEDIATE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate management of the infant or child with hypoglycemia involves obtaining critical samples and administering parenteral glucose. These steps are summarized in a rapid overview (",
"    <a class=\"graphic graphic_table graphicRef83485 \" href=\"mobipreview.htm?31/43/32446\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Critical samples",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the diagnosis of hypoglycemia is suspected and supported by a rapid indicator (eg, a point-of-care measurement) of the blood glucose concentration, sufficient (approximately 5 to 10 mL) blood should be obtained",
"    <strong>",
"     before",
"    </strong>",
"    therapeutic intervention to confirm the diagnosis by an established quantitative laboratory method and to permit additional biochemical tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood should be drawn in the appropriate tubes according to the requirements of individual clinical laboratories. However, most of the studies can be performed on blood treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or EDTA. Blood samples should be transported on ice to the laboratory. Excess plasma should be stored at -70&ordm;C until all the ordered results are available.",
"   </p>",
"   <p>",
"    Blood tests that should be performed immediately include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of key substrates: plasma glucose, FFAs, &szlig;-hydroxybutyrate, lactate, total and free",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      , and acylcarnitines",
"     </li>",
"     <li>",
"      Measurement of glucoregulatory hormones: plasma insulin, C-peptide, cortisol, and growth hormone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other tests that are helpful include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum electrolytes (for calculation of the anion gap)",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Ammonia",
"     </li>",
"     <li>",
"      Toxicology studies (salicylate, ethanol, sulfonylurea)",
"     </li>",
"     <li>",
"      Metabolic screening for some disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the critical blood sample, the first voided urine should be collected. A sample should be tested for ketones (if plasma ketones are not available) and reducing substances. The presence of non-glucose reducing substances in the urine suggests galactosemia or hereditary fructose intolerance if other reducing substances (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    ) are excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30886?source=see_link\">",
"     \"Clinical features and diagnosis of galactosemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remaining urine should be frozen and saved for toxicology studies, organic acids, dicarboxylic acids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acylglycines if indicated by subsequent evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Glucose therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6151672\">",
"    <span class=\"h4\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is conscious and able to drink and swallow safely, a rapidly-absorbed carbohydrate (eg, glucose tablets, glucose gel, table sugar, fruit juice, or honey) should be given by mouth. Administer 0.3",
"    <span class=\"nowrap\">",
"     grams/kg",
"    </span>",
"    (10 to 20 grams) of a rapidly-absorbed carbohydrate. This can be supplied by 2 to 3 glucose tablets, a tube of gel with 15 grams, 4 oz (120 mL) sweetened fruit juice, non-diet soda, or a teaspoon (5 mL) of honey or table sugar. This process may be repeated in 10 to 15 minutes. However, if the hypoglycemia does not improve within 15 to 30 minutes, parenteral glucose must be seriously considered and is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6151735\">",
"    <span class=\"h4\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with altered consciousness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are unable to safely a swallow rapidly absorbed carbohydrate should be treated with intravenous (IV) dextrose. While placing the intravenous lines, subcutaneous or intramuscular",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    should be considered.(See",
"    <a class=\"local\" href=\"#H14\">",
"     'Glucagon'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial bolus of dextrose, 0.25",
"      <span class=\"nowrap\">",
"       grams/kg",
"      </span>",
"      of body weight. This is usually achieved with 2.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 10 percent dextrose solution, since extravasation of higher concentrations of glucose will lead to severe tissue damage. The bolus should be administered slowly (2 to 3",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      regardless of age. Somewhat lower concentration of dextrose solution is often used for management of hypoglycemia in neonates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"       \"Neonatal hypoglycemia\"",
"      </a>",
"      .) The infusion is given slowly to avoid acute hyperglycemia, which can cause rebound hypoglycemia.",
"     </li>",
"     <li>",
"      After the bolus, plasma glucose should be maintained by an infusion of dextrose at 6 to 9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute. The rate of glucose infusion",
"      <span class=\"nowrap\">",
"       (mg/kg",
"      </span>",
"      per minute) can be calculated as follows:",
"      <br/>",
"      <br/>",
"      Rate of infusion",
"      <span class=\"nowrap\">",
"       (mg/kg",
"      </span>",
"      per min) = (Percent dextrose in solution x 10 x rate of infusion [mL per hr]) &divide; (60 x weight [kg])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher doses of dextrose (eg, 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    have been recommended for the initial bolus. However, our clinical experience in children and infants, and studies in adults, suggest that such doses are excessive and are likely to cause acute hyperglycemia, hyperinsulinemia, and hyperosmolarity, which may result in recurrence of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic hypoglycemia caused by sulfonylurea overdose is managed with boluses of dextrose as described above, with close monitoring for recurrent hypoglycemia. If hypoglycemia recurs or becomes more severe,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37991?source=see_link\">",
"     octreotide",
"    </a>",
"    should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13687?source=see_link\">",
"     \"Sulfonylurea agent poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucagon",
"    </span>",
"    &nbsp;&mdash;&nbsp;If IV access is not readily available and the patient is unable to safely swallow a rapidly absorbed carbohydrate, hypoglycemia may be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    , given intramuscularly or subcutaneously (0.03",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum of 1 mg). Glucagon is generally effective for initial treatment of hypoglycemia caused by hyperinsulinemia (eg, in a patient with diabetes treated with exogenous insulin). The response is frequently transient. Thus, if the hyperinsulinemia persists, repeated administration of glucose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucagon may be required. The response to glucagon also may provide diagnostic information for patients in whom the etiology of hypoglycemia is unknown. (See",
"    <a class=\"local\" href=\"#H6857143\">",
"     'Glucagon challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the initial treatment phase, the plasma glucose should be monitored every 30 to 60 minutes and the dextrose infusion adjusted accordingly, until a stable plasma glucose concentration between 70 and 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.9 to 6.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is attained. Thereafter, plasma glucose should be monitored every two to four hours. Hyperinsulinemia is suggested when rates of glucose infusion greater than 6 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute are necessary to maintain normal plasma glucose concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous diagnostic procedures are available to clarify the pathogenesis of the various hypoglycemic disorders, but a systematic approach will yield the most interpretable results. The results obtained from the history, physical examination, and initial plasma samples should guide further testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history in a hypoglycemic child should include a thorough exploration of the past medical history (including perinatal history), details of the acute event as well as previous episodes, and family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perinatal history should include the birth weight, gestational age, and whether the child had hypoglycemic symptoms at birth or in the neonatal period. It is important to explore the child's past medical history, and to review available medical records, to determine whether the child had other episodes suggestive of hypoglycemia that may have been missed or diagnosed as other conditions (eg, seizure disorder, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Age at onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;What was the age at the onset of symptoms? Inborn errors of metabolism and congenital hormone deficiencies usually present in the neonatal period or the first two years of life; ketotic hypoglycemia, isolated growth hormone deficiency, and cortisol deficiency are usually present after 1 year of age. Ingestion should be considered in children who present as toddlers and young children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The details of the acute event should include information about the child's dietary intake before the event. Did acute illness prevent the child from achieving adequate carbohydrate intake? Was the child in the fed or fasting condition at the time of hypoglycemia? All of this information can help to narrow the differential diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms after ingestion of milk products or fructose may indicate galactosemia or hereditary fructose intolerance, respectively.",
"     </li>",
"     <li>",
"      Children who have hereditary defects of amino acid or organic acid metabolism may develop hypoglycemia shortly after the ingestion of protein. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Was there a history of ingestion, or opportunity for ingestion of alcohol, oral hypoglycemic agents,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , beta blockers, or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/12/19655?source=see_link\">",
"       quinine",
"      </a>",
"      (all of which can cause hypoglycemia in children)? Was there ingestion of foods containing toxins (eg, unripened ackee fruit, a staple in Jamaican diets)? (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=see_link\">",
"       \"Approach to the child with occult toxic exposure\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of Reye syndrome, unexplained infant deaths, or other affected family members suggests an inborn error of metabolism, particularly a fatty acid oxidation defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/4,12,13\">",
"     4,12,13",
"    </a>",
"    ]. Hormonal deficiencies and hyperinsulinism also may run in families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology of hypoglycemia in infants and children\", section on 'Disorders of fatty acid metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination may provide important clues to the diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child's weight and length or height should be measured and plotted on an appropriate growth chart, and the child's growth trajectory should be evaluated. Short stature may indicate hypopituitarism or growth hormone deficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=see_link\">",
"       \"Causes of short stature\"",
"      </a>",
"      .) Disorders of amino acid, organic acid, and carbohydrate metabolism are usually associated with failure to thrive, whereas children with fatty acid oxidation disorders typically have normal growth. Children who are underweight for age may be at risk for ketotic hypoglycemia; poor weight gain also may be caused by hypopituitarism and ACTH unresponsiveness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Midline facial defects (eg, a single central incisor, optic nerve hypoplasia, cleft lip or palate) and microphallus or undescended testicles in boys may indicate hypopituitarism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      growth hormone deficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=see_link\">",
"       \"Diagnosis of growth hormone deficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Macrosomia, hepatosplenomegaly, and umbilical hernia may indicate Beckwith-Wiedemann syndrome, whereas hepatomegaly and hypotonia may indicate a glycogen storage disease, defects in gluconeogenesis, galactosemia, or hereditary fructose intolerance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperventilation may be a clue to metabolic acidosis from an inborn error of metabolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperpigmentation may be a clue to adrenal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Elective fast",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most children with a history of hypoglycemia, a diagnostic fast under carefully controlled conditions should be considered. Because of the potential risk of provoking an episode of severe encephalopathy in a child with a defect in fatty acid or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    metabolism, the plasma carnitine concentration (and plasma concentrations of the acylcarnitines) should be proven to be normal before initiating an elective fast.",
"   </p>",
"   <p>",
"    The duration of the fast depends upon the child's age and normal feeding pattern. For infants and very young children who are normally fed every four to six hours, the fast may consist of omitting one or more feedings. For an older child, who by history, typically fasts overnight, a 24- to 30-hour fast should be initiated after the evening meal. Children fasted according to such a protocol are at risk to develop hypoglycemia between 10:00 AM and 6:00 PM, a time during which they should be awake and alert, and the availability of the physician and laboratory staff is optimal.",
"   </p>",
"   <p>",
"    During the fast, plasma concentrations of glucose, ketone bodies, lactate, alanine, and insulin should be serially monitored and compared with normal standards. Plasma concentrations of growth hormone and cortisol should be obtained at the time of hypoglycemia (although their interpretation is not always clear).",
"   </p>",
"   <p>",
"    Hypoglycemia without (or with only minimal) hepatomegaly and the absence of substantial ketonuria or ketonemia should focus attention on abnormalities of insulin secretion, or disorders of ketogenesis or fatty acid oxidation. Hyperinsulinism is best documented by obtaining a number of plasma samples for simultaneous determination of the glucose and insulin levels at times of hypoglycemia. The plasma insulin concentration after 24 hours of fasting in normal children, depending upon the laboratory assay used, is usually &lt;15",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    (2",
"    <span class=\"nowrap\">",
"     mcU/mL)",
"    </span>",
"    and rarely greater than 35",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mcU/mL),",
"    </span>",
"    except in markedly obese children. Plasma insulin concentrations greater than 35",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mcU/mL)",
"    </span>",
"    with concomitant blood glucose value less than 2.8 mM (50",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    regardless of the period of fasting, are distinctly abnormal and are indications for further studies to document potential hyperinsulinemia.",
"   </p>",
"   <p>",
"    If the patient becomes hypoglycemic (plasma glucose &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.2 mM]), a",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    challenge test should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6857143\">",
"    <span class=\"h2\">",
"     Glucagon challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of a child with hypoglycemia of unknown cause, a",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    challenge test (or glucagon stimulation test) at the time of hypoglycemia can provide very useful diagnostic information about glycogen stores. Following infusion (or IM injection) of glucagon (0.03 mg per kg), the glycemic response should be measured at 10, 20, and 30 minutes. A clear glycemic response (&gt;20 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1 to 2",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    during the first 10 to 20 minutes) in a hypoglycemic child suggests inappropriate sequestration of hepatic glycogen caused by hyperinsulinemia, which may be of endogenous or exogenous origin. Since the beta cell co-secretes C-peptide in equimolar amounts with insulin, the plasma C-peptide concentrations reflect endogenous insulin secretion. Therefore, a low C-peptide concentration in a patient with a positive glycemic response to a glucagon challenge indicates that the source of the insulin is exogenous.",
"   </p>",
"   <p>",
"    Plasma insulin levels may be either high or low in patients whose hypoglycemia is caused by covert exogenous administration of insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/22\">",
"     22",
"    </a>",
"    ]. This is because recombinant modified human insulins may not be detected in the new monoclonal sandwich assays used by many commercial laboratories to measure specifically unmodified human insulin. Thus, if measured plasma insulin concentrations are low (and the C-peptide level is also low), polyclonal insulin assays must be sought to detect exogenous insulin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=see_link&amp;anchor=H21#H21\">",
"     \"Etiology of hypoglycemia in infants and children\", section on 'Hyperinsulinism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other provocative tests may be considered in children with suspected defects in gluconeogenesis (eg, galactose, fructose, and alanine tolerance tests) or with hyperinsulinemia (Ca++, leucine). However, as a general rule, these tests should be performed only in selected circumstances and by individuals who are experienced in their performance and interpretation.",
"   </p>",
"   <p>",
"    Samples for DNA analysis should be considered in conditions for which good clinical probes are available. Liver biopsy may, rarely, be necessary to measure deficiencies of hepatic enzymes of glycogenolysis or gluconeogenesis. When necessary, an open biopsy is generally recommended to obtain sufficient tissue for histology, biochemical measurements, and assay of enzyme activity in a specialized laboratory. Tissue samples should be immediately frozen in liquid nitrogen in the operating room and stored at -80&ordm;C until assayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the critical sample is obtained at the time of initial presentation or after an elective fast, the results can help in determining the etiology of hypoglycemia. Assuming that true hypoglycemia occurred, the first step in interpretation is to determine whether the degree of ketosis is appropriate or inappropriate for the degree of hypoglycemia. The degree of ketosis can only be determined by measurement of beta-hydroxybutyrate in the serum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Inappropriate ketosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of only mild or moderate ketosis (beta-hydroxybutyrate of &lt;2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at the time of hypoglycemia in a child indicates that FFAs are not being mobilized appropriately or cannot be used for ketone body formation. These findings suggest hyperinsulinism or fatty acid oxidation defects, respectively.",
"   </p>",
"   <p>",
"    Hyperinsulinemia is the primary diagnostic consideration. A robust glycemic response (&gt;20 to 30",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    at the time of hypoglycemia would further strengthen this possibility. Elevated plasma insulin concentration confirms hyperinsulinemia, but clear and unequivocal elevation of the plasma insulin concentration is frequently not observed. (See",
"    <a class=\"local\" href=\"#H6857143\">",
"     'Glucagon challenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In fatty acid oxidation defects, the plasma FFA concentrations may be very high (&gt;1800 mM) in the face of relatively modest ketonemia, and very low or undetectable plasma insulin concentrations. However, some disorders of FFA oxidation (eg, hydroxyacyl-coenzyme A dehydrogenase, HADH, previously known as short-chain L-3-hydroxyacly CoA dehydrogenase deficiency, SCHAD) can cause disturbance of",
"    <span class=\"nowrap\">",
"     ADP/ATP",
"    </span>",
"    ratios in the beta cell and have been associated with hyperinsulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with glycogen storage disease type I (GSD I, glucose-6-phosphatase deficiency, von Gierke disease) also have relative hypoketonemia. However, additional clinical features permit differentiation of these patients from those with hyperinsulinemia or defects of fatty acid oxidation. Clinical features of glucose-6-phosphatase deficiency include profound hepatomegaly (except in the newborn), hypertriglyceridemia, and failure to generate a clear glycemic response, but dramatic lactate response, following",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    stimulation test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16136?source=see_link\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Appropriate ketosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of ketonemia (beta-hydroxybutyrate &gt;2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    indicates that the child is able to mobilize FFAs and use them for ketone body formation. Diagnostic considerations in these children include a normal fasting response, ketotic hypoglycemia, growth hormone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cortisol deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8201/abstract/24\">",
"     24",
"    </a>",
"    ], some disorders of fatty acid oxidation, and disorders of amino and organic acids. The measurement of qualitative urine organic acids and the presence or absence of hepatomegaly can help to distinguish among these possibilities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia in infants and children requires prompt recognition and treatment to prevent permanent neurologic sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of hypoglycemia include autonomic (adrenergic) symptoms, and neuroglycopenic symptoms. The severity of symptoms may or may not predict the severity of the hypoglycemia. Neuroglycopenic symptoms typically occur at lower blood glucose levels than autonomic symptoms. However, with repeated episodes of hypoglycemia, the threshold glucose concentration for adrenergic symptoms decreases, such that they may not appear before the onset of neuroglycopenic symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autonomic symptoms of hypoglycemia in infants are nonspecific and include irritability, jitteriness, feeding problems, lethargy, cyanosis, and tachypnea. Older children may have the characteristic symptoms due to increased adrenergic activity (sweating, weakness, tachycardia, tremor, and feelings of nervousness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hunger). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Autonomic response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of neuroglycopenia include lethargy, irritability, confusion, behavior that is out of character, hypothermia, and, in extreme hypoglycemia, seizure and coma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neuroglycopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When hypoglycemia is suspected, a rapid (bedside) blood glucose determination should be performed. If it is low (&le;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.2",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      critical samples should be obtained and subsequently treatment should be initiated. Obtaining critical samples before the initiation of therapy, and collecting the first voided urine sample can dramatically improve the ability to diagnose the etiology of the hypoglycemia and greatly simplify the subsequent diagnostic evaluation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Critical samples'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hypoglycemia varies with the degree of hypoglycemia and associated symptoms. The key steps for diagnosis and treatment are summarized in a rapid overview (",
"    <a class=\"graphic graphic_table graphicRef83485 \" href=\"mobipreview.htm?31/43/32446\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Immediate management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is fully conscious and able to drink and swallow safely, a rapidly-absorbed carbohydrate (eg, glucose tablets, glucose gel, table sugar, or fruit juice) should be given by mouth. If the hypoglycemia does not improve within 10 to 15 minutes, parenteral glucose must be administered. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucose therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children with altered consciousness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who are unable to safely swallow a rapidly-absorbed carbohydrate should be treated with intravenous (IV) dextrose, at a dose of 0.25",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of body weight. This is usually achieved with 2.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 10 percent dextrose solution, given slowly (2 to 3",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucose therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subsequent management &ndash; The intravenous bolus described above should be followed by an infusion of dextrose. Plasma glucose should be monitored every 30 to 60 minutes and the dextrose infusion adjusted accordingly, until stable plasma glucose concentration between 70 and 120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9 to 6.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      is attained. Thereafter, frequency of glucose monitoring should be decreased according to the patient's clinical and biochemical responses. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucose therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sulfonylurea overdose &ndash; Symptomatic hypoglycemia caused by sulfonylurea overdose is managed with boluses of dextrose and sometimes also with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37991?source=see_link\">",
"       octreotide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13687?source=see_link\">",
"       \"Sulfonylurea agent poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mild symptoms &ndash; If the hypoglycemia is mild and the patient is able to tolerate an oral carbohydrate, oral glucose administration can be attempted. However, if the hypoglycemia does not improve within 10 to 15 minutes, parenteral glucose must be administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic evaluation depends upon the findings of the history, examination, and preliminary laboratory results. A controlled elective fast may be necessary, but should be performed only after disorders of fatty acid oxidation have been excluded. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/1\">",
"      Cahill GF Jr, Herrera MG, Morgan AP, et al. Hormone-fuel interrelationships during fasting. J Clin Invest 1966; 45:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/2\">",
"      Chaussain JL, Georges P, Calzada L, Job JC. Glycemic response to 24-hour fast in normal children: III. Influence of age. J Pediatr 1977; 91:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/3\">",
"      Haymond MW, Karl IE, Clarke WL, et al. Differences in circulating gluconeogenic substrates during short-term fasting in men, women, and children. Metabolism 1982; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     Darmaun D, Haymond MW, Bier DM. Metabolic aspects of fuel homeostasis in the fetus and neonate. In: Endocrinology, 3rd ed, DeGroot LJ, Besser M, Burger HG, et al (Eds), WB Saunders, Philadelphia 1995. p.2258.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/5\">",
"      Kalhan SC, D'Angelo LJ, Savin SM, Adam PA. Glucose production in pregnant women at term gestation. Sources of glucose for human fetus. J Clin Invest 1979; 63:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/6\">",
"      Sunehag A, Ewald U, Gustafsson J. Extremely preterm infants (&lt; 28 weeks) are capable of gluconeogenesis from glycerol on their first day of life. Pediatr Res 1996; 40:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/7\">",
"      Grajwer LA, Sperling MA, Sack J, Fisher DA. Possible mechanisms and significance of the neonatal surge in glucagon secretion: studies in newborn lambs. Pediatr Res 1977; 11:833.",
"     </a>",
"    </li>",
"    <li>",
"     Cornblath M, Schwartz R. Disorders of Carbohydrate Metabolism in Infancy, Blackwell Publications, Cambridge, MA 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/9\">",
"      Haymond MW, Sunehag A. Controlling the sugar bowl. Regulation of glucose homeostasis in children. Endocrinol Metab Clin North Am 1999; 28:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/10\">",
"      Haymond MW, Howard C, Ben-Galim E, DeVivo DC. Effects of ketosis on glucose flux in children and adults. Am J Physiol 1983; 245:E373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/11\">",
"      Bier DM, Leake RD, Haymond MW, et al. Measurement of \"true\" glucose production rates in infancy and childhood with 6,6-dideuteroglucose. Diabetes 1977; 26:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/12\">",
"      Huopio H, Shyng SL, Otonkoski T, Nichols CG. K(ATP) channels and insulin secretion disorders. Am J Physiol Endocrinol Metab 2002; 283:E207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/13\">",
"      Amiel SA, Simonson DC, Sherwin RS, et al. Exaggerated epinephrine responses to hypoglycemia in normal and insulin-dependent diabetic children. J Pediatr 1987; 110:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/14\">",
"      Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/15\">",
"      Collier A, Steedman DJ, Patrick AW, et al. Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department. Diabetes Care 1987; 10:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/16\">",
"      Wiethop BV, Cryer PE. Alanine and terbutaline in treatment of hypoglycemia in IDDM. Diabetes Care 1993; 16:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/17\">",
"      Haymond MW. Hypoglycemia in infants and children. Endocrinol Metab Clin North Am 1989; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/18\">",
"      Verrotti A, Fusilli P, Pallotta R, et al. Hypoglycemia in childhood: a clinical approach. J Pediatr Endocrinol Metab 1998; 11 Suppl 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/19\">",
"      Stanley CA, Lieu YK, Hsu BY, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998; 338:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/20\">",
"      Roe TF, Kogut MD. Hypopituitarism and ketotic hypoglycemia. Am J Dis Child 1971; 121:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/21\">",
"      Kershnar AK, Roe TF, Kogut MD. Adrenocorticotropic hormone unresponsiveness: report of a girl with excessive growth and review of 16 reported cases. J Pediatr 1972; 80:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/22\">",
"      Green RP, Hollander AS, Thevis M, et al. Detection of surreptitious administration of analog insulin to an 8-week-old infant. Pediatrics 2010; 125:e1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/23\">",
"      Clayton PT, Eaton S, Aynsley-Green A, et al. Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. J Clin Invest 2001; 108:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8201/abstract/24\">",
"      Cornblath M, Pildes RS, Schwartz R. Hypoglycemia in infancy and childhood. J Pediatr 1973; 83:692.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5805 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8201=[""].join("\n");
var outline_f8_0_8201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLUCOSE HOMEOSTASIS IN NORMAL INFANTS AND CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION OF HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY OF HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autonomic response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuroglycopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMMEDIATE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Critical samples",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Glucose therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6151672\">",
"      Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6151735\">",
"      Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucagon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Past medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Age at onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Elective fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6857143\">",
"      Glucagon challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Additional testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INTERPRETATION OF RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Inappropriate ketosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Appropriate ketosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5805|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/49/7966\" title=\"figure 1\">",
"      Glucose disappearance by weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/21/13662\" title=\"figure 2\">",
"      Glucose use brain v nonbrain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/43/32446\" title=\"table 1\">",
"      Rapid overview for hypoglycemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16136?source=related_link\">",
"      Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25511?source=related_link\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41702?source=related_link\">",
"      Insulin secretion and pancreatic beta-cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13687?source=related_link\">",
"      Sulfonylurea agent poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_0_8202="Patterns of relapse and long-term complications of therapy in breast cancer survivors";
var content_f8_0_8202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Arti Hurria, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Steven E Come, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Patricia A Ganz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Larissa Nekhlyudov, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?8/0/8202/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?8/0/8202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide. In the United States, breast cancer is second to lung cancer as the most common cause of cancer death in women, and the main cause of death in women ages 40 to 49 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there has been a decline in breast cancer mortality rates in the United States and elsewhere in the Western world, attributable to the increased use of screening mammography and advances in adjuvant therapies. As a result of improved survival and the aging of the population, there are nearly three million women living with a history of breast cancer in the United States alone, accounting for 41 percent of all female cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/2\">",
"     2",
"    </a>",
"    ]. Breast cancer survivors are the largest constituent of all cancer survivors, representing 3.6 percent of the United States population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of breast cancer recurrences occur within the first five years of diagnosis, particularly with hormone receptor-negative or HER2-positive disease. However, some recurrences occur much later, particularly in the setting of hormone receptor-positive, HER2-negative tumors, which tend to behave more indolently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/5\">",
"     5",
"    </a>",
"    ]. This was shown in a study of 2838 patients with stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    or III breast cancer (",
"    <a class=\"graphic graphic_table graphicRef73355 \" href=\"mobipreview.htm?15/58/16303\">",
"     table 1",
"    </a>",
"    ) who had not recurred within five years of completing initial therapy; recurrence risks in the subsequent 5 and 10 years were still 11 and 19 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse patterns and long-term complications of therapy for invasive breast cancer in women who are at least five years out from their initial diagnosis will be reviewed here. Recommendations for surveillance strategies in breast cancer survivors and an overview of the approach to breast cancer survivors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1203495\">",
"    <span class=\"h1\">",
"     OVERVIEW OF BREAST CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201175\">",
"    <span class=\"h2\">",
"     Treatment overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with breast cancer require a multidisciplinary treatment approach that may include surgery, radiation therapy (RT), and systemic therapy. The following provides a broad overview of contemporary breast cancer treatment (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201190\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with newly diagnosed breast cancer, the extent of surgery depends on whether disease is preinvasive (carcinoma in situ) or invasive.",
"   </p>",
"   <p>",
"    In general, women with in situ breast cancer (DCIS) undergo breast conserving surgery. Axillary node evaluation is not routinely indicated for these women as long as an invasive component is not present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most women with early invasive breast cancer require surgery to remove the primary breast tumor and evaluate ipsilateral axillary nodes. However, some women with early stage disease and most women with locally advanced disease do not undergo primary surgery. Instead, these women are often treated with neoadjuvant systemic therapy prior to definitive surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12586?source=see_link&amp;anchor=H1378592045#H1378592045\">",
"     \"Mastectomy\", section on 'Selection criteria for mastectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link&amp;anchor=H7#H7\">",
"     \"Breast conserving therapy\", section on 'Patient selection for BCT'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H35822834\">",
"     'Chemotherapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35466?source=see_link\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    The removal of lymph nodes for women with invasive breast cancer gives important staging information and is used to make further treatment decisions. Sentinel lymph node biopsy is less morbid than axillary lymph node dissection and results in similar survival outcomes. Therefore, women with early stage breast cancer without evidence of clinical axillary node involvement typically undergo a sentinel node procedure. Patients who are found to have more than three positive sentinel nodes may require a completion axillary node dissection. For those with more than three pathologically involved nodes, a decision about axillary node dissection is made on an individualized basis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women who present with metastatic disease (outside the breast and axilla), systemic therapy is usually administered. However, surgery may play a role in symptom management. In these cases, decisions regarding surgery are based on individual consideration of symptoms and disease characteristics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35831?source=see_link\">",
"     \"Metastatic breast cancer: Local treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4292?source=see_link\">",
"     \"Role of breast surgery for stage IV breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201197\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast radiation therapy (RT) is an important component of breast conserving therapy for both in situ and invasive breast cancer. RT may also be administered to some women following a mastectomy, particularly those with large tumors (ie, &gt;5 cm), positive margins, and those with nodal involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12586?source=see_link\">",
"     \"Mastectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35822819\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine therapy is appropriate treatment for patients with estrogen (ER) or progesterone (PR) receptor-positive tumors. In most patients, treatment options in the adjuvant setting are made using the same general principles:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For women with DCIS, five years of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      treatment following breast surgery is often considered to reduce the risk of in-breast tumor recurrence and contralateral breast events. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=see_link&amp;anchor=H641529608#H641529608\">",
"       \"Ductal carcinoma in situ: Treatment and prognosis\", section on 'Tamoxifen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For premenopausal women, there are several options available including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or ovarian",
"      <span class=\"nowrap\">",
"       suppression/ablation.",
"      </span>",
"      Aromatase inhibitors (AIs) are generally avoided because of the lack of evidence that AIs adequately suppress estrogen, and the potential that AI will increase gonadotropin release and result in stimulation of ovarian function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H658260#H658260\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Premenopausal women'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For postmenopausal women, standard treatment in the adjuvant setting include (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H658253#H658253\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Postmenopausal women'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Treatment with an AI (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      ) for five years",
"     </li>",
"     <li>",
"      Sequential treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or an AI for two to three years followed by the alternative agent for three to two years (for a five year total treatment course)",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for five years",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for five years followed by an AI for an additional five years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endocrine therapy may be used as neoadjuvant treatment of locally advanced hormone-positive breast cancer or as primary treatment for older women who are medically unfit for chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35466?source=see_link&amp;anchor=H19285752#H19285752\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\", section on 'Endocrine therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocrine therapy is also preferred treatment for women with metastatic breast cancer with limited disease (ie, isolated to the bones) and those who are asymptomatic. The choice of treatment is based on the menstrual status of the woman at the time of diagnosis of metastatic disease and whether or not prior treatment was administered (ie, as adjuvant treatment). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35822834\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy is generally recommended for women with invasive breast cancer with hormone receptor-negative tumors or higher risk hormone receptor-positive tumors. For women with hormone receptor-positive tumors, molecular assays are available to identify patients at high risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H3290799#H3290799\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Estimating risks and benefits'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple adjuvant options are used, although a regimen containing taxane and anthracycline is commonly used for patients with node-positive tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy is also administered prior to surgery (ie, neoadjuvant therapy) for women who present with locally advanced breast cancer and in those women who are not candidates for breast conserving surgery at the time of presentation, although women with smaller tumors at the time of presentation may have received neoadjuvant chemotherapy as well. The clinical objective of treatment is to induce a tumor response to improve the chances for breast conserving surgery. However, there is no evidence that neoadjuvant chemotherapy improves survival outcomes (compared to surgery followed by adjuvant treatment). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35466?source=see_link\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with advanced or metastatic breast cancer, chemotherapy is indicated for women who progress on or following endocrine treatment and those women with visceral metastatic disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cancer-related symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35822944\">",
"    <span class=\"h2\">",
"     Anti-HER2 directed treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    is recommended in addition to standard adjuvant chemotherapy for patients with human epidermal growth factor 2 (HER2) receptor-positive invasive breast cancers that is either node-positive or node-negative with high risk features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-HER2 directed treatment is also administered in the neoadjuvant setting for women with locally advanced breast cancer and in the treatment of HER2-positive metastatic breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35466?source=see_link&amp;anchor=H541773077#H541773077\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\", section on 'HER2-directed therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELAPSE PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who were treated for invasive breast cancer are at risk of both a locoregional recurrence and the evolution of metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Locoregional recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have undergone either mastectomy or breast conserving surgery are at risk for locoregional recurrence. For women treated for early breast cancer, the recurrence rate ranges from 4 to 7 percent with mastectomy or breast conserving therapy (BCT), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Locoregional recurrences tend to occur later in women treated with BCT compared to those who underwent a mastectomy. In either case, potentially curative surgery may be an option. The surgical approach depends on whether or not RT (and the type of RT) was previously administered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, women treated with BCT (including adjuvant RT) should proceed with a mastectomy because reirradiation is not generally an option to reduce the risk of another local recurrence. However, for women who did not previously receive RT and those treated with partial breast irradiation, re-excision may be appropriate because they may be candidates for RT.",
"     </li>",
"     <li>",
"      In contrast, a local recurrence following mastectomy is usually manifest as a mass in the chest wall, regional nodal basins (ie, infraclavicular, supraclavicular, and axillary regions), or overlying skin. Treatment may involve excision of the recurrence or RT (if not previously administered). However, if relapse occurs within two years of primary treatment, distant metastatic disease is already present in 25 to 30 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/8\">",
"       8",
"      </a>",
"      ]. Therefore, systemic therapy is generally administered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=see_link\">",
"       \"Management of locoregional recurrence of breast cancer after breast conserving therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link\">",
"       \"Management of locoregional recurrence of breast cancer after mastectomy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although approximately 15 to 40 percent of recurrences involve the chest wall and axillary or supraclavicular lymph nodes, breast cancer has the potential to metastasize to almost every organ in the body (",
"    <a class=\"graphic graphic_table graphicRef80826 \" href=\"mobipreview.htm?25/53/26459\">",
"     table 2",
"    </a>",
"    ). The most common sites of metastases are bone, liver, and lung. Approximately 50 to 75 percent of patients who relapse distantly do so in a single organ; the remainder will develop diffuse metastatic disease. Fewer than 5 percent of patients will manifest central nervous system (CNS) involvement as the first site of metastatic disease. The treatment approach to women presenting with metastatic breast cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35831?source=see_link\">",
"     \"Metastatic breast cancer: Local treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1199208\">",
"    <span class=\"h1\">",
"     SECOND PRIMARY BREAST TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a second breast cancer is the same whether a patient was treated by mastectomy or breast conserving therapy (BCT). For women without an inherited predisposition to breast cancer (ie, a BRCA1 or BRCA2 mutation), this risk is between 0.5 to 1.0 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. For women with a known genetic predisposition, the risk is much higher. The lifetime risk of contralateral recurrence may be as high as 65 percent for BRCA1 mutation carriers and 50 percent for BRCA2 carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H10#H10\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Breast cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A substantial number of second primary breast cancers occur after five years, necessitating long-term surveillance for all women with a history of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This is especially true for hormone receptor-positive breast cancers. As an example, in National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-04, which evaluated mastectomy with and without RT, 50 percent of all contralateral breast cancers were detected after five years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link&amp;anchor=H560048#H560048\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Breast imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LONG-TERM ADVERSE EFFECTS OF PRIMARY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most breast cancer survivors report good quality of life, but some patients may have chronic difficulties associated with role, emotional, cognitive, and social functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Fatigue, cognitive dysfunction, difficulties with sleep, pain, and menopausal symptoms can be chronic and debilitating.",
"    <strong>",
"    </strong>",
"    The various long-term physical and psychological sequelae due to specific breast cancer treatments are summarized in the following (",
"    <a class=\"graphic graphic_table graphicRef81721 \" href=\"mobipreview.htm?4/44/4813\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201318\">",
"    <span class=\"h2\">",
"     Chest wall and breast complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast surgery, breast reconstruction, and radiation therapy (RT) may result in long-term complications in the breast and chest wall. These include formation of seromas, fat necrosis, and recurrent skin infections (cellulitis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=see_link&amp;anchor=H18#H18\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to surgical complications, RT may result in long-term issues, including the rare complication of late soft tissue necrosis, which affects 0.2 percent of patients undergoing RT for early stage breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201327\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast and axillary surgery also can result in musculoskeletal issues including reduced arm mobility. RT may compound surgery-related pain and motor restriction, both in the short and long term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/19\">",
"     19",
"    </a>",
"    ]. Rib fractures from RT may occur as late complications in 2 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most women will not require endocrine therapy past five years, although a subset will. For women treated with an aromatase inhibitor (AI) following a five year course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , AI treatment can cause muscle and joint pains resulting in treatment discontinuation in up to 20 percent of patients. In addition to these complaints, treatment with an AI increases the risk for osteoporosis and subsequent fractures. In one study, patients taking an AI had a 35 percent higher rate of fracture compared to those not on an AI (rate of 8.6 versus 6.4 events per 100 person-years; RR 1.35, 95% CI 1.16-1.58) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H2110938459#H2110938459\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1202250\">",
"    <span class=\"h2\">",
"     Lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both breast surgery and radiation can lead to the development of early- or delayed-onset lymphedema, which can involve the breast, chest, and the ipsilateral extremity. Rates of lymphedema are highest in women who undergo mastectomy with axillary lymph node dissection followed by chest wall and axillary RT. In patients who present with lymphedema late, it is important to evaluate for alternate causes of new swelling including tumor recurrence, infection, and thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H884706130#H884706130\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Cancer and cancer treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201336\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast surgery can cause nerve injury, which may result in long-term symptoms of paresthesias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent pain in the chest wall. In addition, RT can result in a brachial plexopathy, manifest as paresthesia or weakness in the arm or hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=see_link\">",
"     \"Complications of peripheral nerve irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurotoxicity is also a well-recognized side effect of adjuvant chemotherapy, particularly with taxanes. The peripheral neuropathy that develops after taxanes is often reversible after treatment discontinuation, but in rare instances, the neuropathy is permanent. Neuropathy may be painful and interfere with activities of daily living. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H12#H12\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Taxanes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201402\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT to the breast can result in pneumonitis, which typically presents as a persistent dry cough or shortness of breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/18\">",
"     18",
"    </a>",
"    ]. Fortunately, with modern RT techniques it is a rare event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1202380\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sense of fatigue may persist in survivors for years after cessation of treatment. In one study, for example, approximately 30 percent of breast cancer survivors had moderate to severe fatigue more than two years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/22\">",
"     22",
"    </a>",
"    ]. Before assuming that fatigue is related to prior treatment for breast cancer, treatable reasons for low energy should be ruled out, including anemia, thyroid dysfunction, pain, depression, and lack of sleep. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Time course'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Treatable contributing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease may be a complication of breast RT and specific agents used in the treatment of breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541709382\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies with RT in breast cancer patients established a link between incidental RT to the heart and a late increase in the frequency of cardiovascular disease. However, improvement in RT techniques has significantly decreased the amount of incidental radiation received by the heart, and the available data suggest that these technical advances have reduced the incidence of cardiovascular complications. More recent trials using modern RT techniques have found no increase in cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/23\">",
"     23",
"    </a>",
"    ]. However, RT that involves the internal mammary nodes may be associated with a persistent treatment-related cardiovascular toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=see_link&amp;anchor=H6#H6\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'The IM nodes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H730200#H730200\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits of regional nodal irradiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link&amp;anchor=H11#H11\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Postmastectomy irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541709389\">",
"    <span class=\"h3\">",
"     Systemic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to chemotherapeutic and biologic agents, such as anthracyclines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , can result in cardiac morbidity. In a 2012 study that included 12,500 women with invasive breast cancer, the five-year cumulative incidence of cardiovascular disease (defined as heart failure or cardiomyopathy) was increased in the following groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older women &mdash; The incidence was 6 and 11 percent among women aged 65 to 74 and &ge;75 years, respectively. By contrast, the cumulative incidence was one to two percent in younger women.",
"     </li>",
"     <li>",
"      Women treated with chemotherapy &mdash; Women who received an anthracycline had a cumulative incidence of four percent, which was compared to patients who did not receive chemotherapy, represented an increased risk (HR 1.4, 95% CI 1.11-1.76). In addition, women treated with other chemotherapy agents were also at an increased risk (incidence 4.5 percent; HR 1.49, 95% CI 1.25-1.77).",
"     </li>",
"     <li>",
"      Women treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      &mdash; Women treated with an anthracycline plus trastuzumab had a cumulative incidence of 20 percent, which represented an increased risk compared to patients who did not receive chemotherapy (HR 7.19, 95% CI 5 to 10.4). The risk was also increased among patients treated with trastuzumab without an anthracycline (HR 4.12, 95% CI 1.11-1.76)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of cardiomyopathy and heart failure secondary to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    is dose-dependent, typically occurring at higher doses than those administered in the adjuvant setting. The risk increases substantially at cumulative doses greater than 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast to cardiotoxicity from anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -related cardiotoxicity does not appear to be related to cumulative dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541709417\">",
"    <span class=\"h3\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AIs, used in the treatment of hormone-positive postmenopausal breast cancers, may increase the risk of cardiovascular adverse events compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , although the overall risk appears to be low and remains not fully characterized. In a meta-analysis of seven adjuvant trials (n=19,818 patients), compared to tamoxifen, AIs were associated with an increased risk of cardiovascular adverse events (relative risk [RR] 1.31, 95% CI 1.07-1.60), which translated into a number needed to harm of 189 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Second cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although difficult to quantify, there is an increased risk for second cancers associated with breast cancer treatment, whether RT, chemotherapy, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Second cancers that have been associated with breast cancer treatment include esophageal, lung, uterine, and ovarian cancers as well as melanoma, soft tissue sarcoma (notably angiosarcoma), acute myeloid leukemia, and myelodysplastic syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of second malignancies is dependent upon treatment factors (type of treatment, including dose and duration of exposure), lifestyle factors (including a history of smoking or alcohol use), and genetic susceptibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541709403\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with adjuvant RT are at risk for radiation-induced solid tumors and myeloid neoplasms (both acute myeloid leukemia and myelodysplastic syndrome), all of which occur with different frequencies according to the length of time following treatment. As an example, in one study, secondary leukemias (usually myeloid) tend to occur within five to seven years; solid tumors, including esophageal cancer, usually present at least 10 years after radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, radiation-induced angiosarcoma typically presents with a latency period of five to eight years. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30359?source=see_link&amp;anchor=H949706103#H949706103\">",
"     \"Complications of breast and chest wall irradiation for early stage breast cancer\", section on 'Secondary malignancies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541709410\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cumulative incidence of developing treatment-related acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) is generally less than 1 percent, but corresponds to a twofold increased risk of",
"    <span class=\"nowrap\">",
"     AML/MDS",
"    </span>",
"    for patients treated with adjuvant therapy as compared to controls (five excess cases per 10,000 treated patients at 10 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/28-30,33-43\">",
"     28-30,33-43",
"    </a>",
"    ]. Two-thirds of these patients are first recognized by evidence of myelodysplasia (usually trilineage dysplasia), marrow failure, and pancytopenia. In general, treatment-related leukemias are more refractory to conventional antileukemic therapy, and they have a very poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556219388\">",
"    <span class=\"h2\">",
"     Cognitive dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of disability associated with treatment-related cognitive dysfunction (eg, impaired memory and decreased ability to concentrate, also known as &ldquo;chemo-brain&rdquo;) is not well characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. A 2012 meta-analysis of 17 studies compared patients who received chemotherapy (n=807) or local or endocrine therapy (n=391) to individuals without a history of cancer (controls, n=291) and reported the following effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with chemotherapy had significantly worse verbal ability (eg, word-finding difficulties) compared to controls (effect size -0.02, 95% CI -0.12 to 0.08), but there were no differences compared with their own pre-chemotherapy baseline or to patients not treated with chemotherapy. These patients also had worse visuospatial ability (eg, &ldquo;getting lost easily&rdquo;) compared to patients not treated with chemotherapy (effect size -0.27, 95% CI -0.45 to -0.08), although there were no differences compared with their own baseline or to controls.",
"     </li>",
"     <li>",
"      Patients treated with chemotherapy had a trend towards worse performance in executive functioning (effect size -0.12, 95% CI -0.23 to 0.00), but this was not statistically significant.",
"     </li>",
"     <li>",
"      Endocrine therapy, age, and time since chemotherapy did not moderate the impact of chemotherapy within these cognitive domains, which were all deemed of small effect sizes (trivial effect defined as size -0.10).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This meta-analysis suggests that cognitive dysfunction related to chemotherapy may be an issue for breast cancer survivors, but the extent of the deficit appears small. In addition, symptoms appear to stabilize with the passage of time.",
"   </p>",
"   <p>",
"    Patients considering chemotherapy may be counselled that the acute effect of treatment on cognitive functioning stabilizes six months following completion of treatment (the cutoff point used in this study). However, patients may be aware of minor cognitive dysfunction affecting verbal and visuospatial abilities. Strategies to compensate for these difficulties should be discussed with the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ovarian failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovaries of premenopausal women who received chemotherapy typically have normal to mildly decreased numbers of primordial follicles and a greater decrease in the numbers of maturing follicles, indicating a greater effect on follicular development than on oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Consistent with these histologic findings are the clinical observations that many women are amenorrheic during chemotherapy, often with high serum gonadotropin concentrations, but that menstrual function and fertility often return several months to years after the cessation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\", section on 'Chemotherapy-induced amenorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women who develop long-term, chemotherapy-induced ovarian failure, the adverse effects of premature menopause may be significant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to management of ovarian failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Psychological effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women may experience heightened anxiety after the completion of therapy. This can be attributed to worry about the risk of recurrence and the loss of the security that many feel while they are actively undergoing therapy. Feelings of uncertainty can persist for years. Dealing with this uncertainty is often the most difficult part of the recovery, and fear of recurrence may extend well past the initial five years of cancer survivorship.",
"   </p>",
"   <p>",
"    An example of the long-term psychologic complications comes from a 20-year follow-up study involving 153 patients who participated in a phase III clinical trial conducted by the Cancer and Leukemia Group B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/54\">",
"     54",
"    </a>",
"    ]. Although the incidence of clinical distress was only five percent in this study, 15 percent had two or more symptoms of post-traumatic stress disorder (PTSD). Statistically significant factors associated with PTSD included lower level of education, less social support availability, more negative life events, and a greater sense of dissatisfaction with medical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541709437\">",
"    <span class=\"h1\">",
"     APPROACH TO THE LONG-TERM SURVIVOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American Society of Clinical Oncology (ASCO) suggest that if a patient with early stage breast cancer (tumor &lt;5 cm and fewer than four positive nodes) desires follow-up exclusively with a primary care physician (PCP), care may be transferred approximately one year after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?8/0/8202/abstract/55\">",
"     55",
"    </a>",
"    ]. In such cases, both the patient and the PCP should be advised of the appropriate follow-up and management strategy.",
"   </p>",
"   <p>",
"    For patients receiving adjuvant hormonal therapy, informed decisions regarding long-term options are best managed with referral for oncology assessment, as endocrine strategies are evolving over time. Additionally, oncologic consultation is indicated if there is suspicion or evidence of disease recurrence, or questions arise regarding the safety of certain interventions (eg, vaginal estrogen in a patient who has severe atrophic vaginitis despite nonhormonal remedies).",
"   </p>",
"   <p>",
"    Breast cancer survivors should receive ongoing age-appropriate screening studies and preventive care, consistent with recommendations for the general population, for conditions other than those related to breast cancer and its treatment. Patients with a history of breast cancer are recommended to undergo regular follow-up to include interim medical history, physical examination, evaluation and management of treatment-related late effects, and breast imaging to assess for recurrence or new primary disease.",
"   </p>",
"   <p>",
"    Data are sparse to inform optimal follow-up of male breast cancer survivors; recommendations for women are usually applied to men, with modification as appropriate.",
"   </p>",
"   <p>",
"    A more extensive discussion on the follow-up of long-term breast cancer survivors is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32247236\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide. In the United States, breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 49 years. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have undergone either mastectomy or breast conserving therapy (BCT) are at risk for locoregional recurrence. For women treated for early breast cancer, the recurrence rate ranges from 4 to 7 percent with mastectomy or breast conserving therapy (BCT), respectively. Women who undergo BCT without radiation therapy (RT) have a much higher rate of local recurrence compared to those who receive RT. Local failures tend to occur later after BCT than after mastectomy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Locoregional recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic counselling and testing should be discussed with patients if there is also a family history of breast or ovarian cancer or if the breast cancer occurred at age 50 or younger. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H10#H10\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Breast cancer'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common sites of metastases are bone, liver, and lung. Approximately 50 to 75 percent of patients who relapse distantly do so in a single organ; the remainder will go on to develop diffuse metastatic disease. (See",
"      <a class=\"local\" href=\"#H1199208\">",
"       'Second primary breast tumors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast surgery, breast reconstruction, and RT may result in long-term complications in the breast and chest wall. These include formation of seromas, recurrent skin infections, and rarely, soft tissue necrosis. (See",
"      <a class=\"local\" href=\"#H1201318\">",
"       'Chest wall and breast complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Musculoskeletal complications can also be attributed to several modalities used to treat breast cancer. This includes reduced arm mobility and lymphedema secondary to surgery; pain, motor restriction, and a higher risk of fractures secondary to RT; and muscle and joint pains due to aromatase inhibitors. (See",
"      <a class=\"local\" href=\"#H1201327\">",
"       'Musculoskeletal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both breast surgery and radiation can lead to the development of lymphedema of the breast, chest, arm, and hand. Rates of lymphedema are highest in women who undergo mastectomy with full axillary lymph dissection plus chest wall and axillary RT. (See",
"      <a class=\"local\" href=\"#H1202250\">",
"       'Lymphedema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast surgery, RT, and chemotherapy can be associated with nerve injury, which can cause long-term symptoms of paresthesias, weakness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent pain. (See",
"      <a class=\"local\" href=\"#H1201336\">",
"       'Neurologic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatigue may persist in survivors for years after cessation of treatment. Before assuming that fatigue is related to prior treatment for breast cancer, treatable reasons for low energy should be ruled out, including anemia, thyroid dysfunction, pain, depression, and lack of sleep. (See",
"      <a class=\"local\" href=\"#H1202380\">",
"       'Fatigue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiovascular disease may be a complication of breast RT and specific agents used in the treatment of breast cancer, especially anthracyclines and the HER2-directed agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , especially in combination with left sided breast irradiation. Symptoms of early congestive heart failure should prompt a cardiac evaluation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiovascular morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an increased risk for second cancers associated with breast cancer treatment, whether breast irradiation, chemotherapy, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Second cancers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of disability associated with treatment-related cognitive dysfunction appears to be small. Cognitive ability stabilizes approximately six months following completion of treatment, though patients may be at risk for minor issues related to verbal and visuospatial abilities. (See",
"      <a class=\"local\" href=\"#H556219388\">",
"       'Cognitive dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women may experience heightened anxiety after the completion of therapy, particularly worried about the risk of recurrence. Fear of recurrence can persist for years. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Psychological effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast cancer survivors should receive ongoing age-appropriate screening and preventive care, consistent with recommendations for the general population, for conditions other than those related to breast cancer and its treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"       \"Approach to the long-term survivor of breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a history of breast cancer should undergo regular follow-up including medical history, physical examination, surveillance mammography, evaluation and management of treatment-related late effects, including assessment of psychosocial distress. Breast MRI for surveillance should not be performed as part of routine surveillance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"       \"Approach to the long-term survivor of breast cancer\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Data are sparse to inform optimal follow-up of male breast cancer survivors; recommendations for women are usually applied to men, with modification as appropriate. (See",
"      <a class=\"local\" href=\"#H541709437\">",
"       'Approach to the long-term survivor'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=see_link\">",
"       \"Breast cancer in men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mortality tables file://www.cdc.gov/nchs/nvss/mortality_tables.htm#lcod (Accessed on April 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/2\">",
"      Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220.",
"     </a>",
"    </li>",
"    <li>",
"     Hewitt, M, Greenfield, S, Stovall, E, et al. From cancer patient to cancer survivor: Lost in transition. (National Academies Press, Washington DC), 2006 file://www.iom.edu/Reports/2005/From-Cancer-Patient-to-Cancer-Survivor-Lost-in-Transition.aspx (Accessed on January 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/4\">",
"      Stat bite: Cancer survivors in the United States. J Natl Cancer Inst 2008; 100:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/5\">",
"      Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/6\">",
"      Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008; 100:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/7\">",
"      Yang SH, Yang KH, Li YP, et al. Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 2008; 19:1039.",
"     </a>",
"    </li>",
"    <li>",
"     Kramer R, Osborne CK.. Kramer, R, Osborne, CK.. In: Diseases of the Breast, 3rd, Harris JR, Lippman ME, Morrow M, Osborne CK (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.1057.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/9\">",
"      Schell SR, Montague ED, Spanos WJ Jr, et al. Bilateral breast cancer in patients with initial stage I and II disease. Cancer 1982; 50:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/10\">",
"      Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984; 71:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/11\">",
"      Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27:5887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/12\">",
"      Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/13\">",
"      Kattlove H, Winn RJ. Ongoing care of patients after primary treatment for their cancer. CA Cancer J Clin 2003; 53:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/14\">",
"      Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/15\">",
"      Arndt V, Merx H, Stegmaier C, et al. Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer. J Clin Oncol 2005; 23:4945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/16\">",
"      Ganz PA, Kwan L, Stanton AL, et al. Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 2011; 29:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/17\">",
"      Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011; 29:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/18\">",
"      Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:915.",
"     </a>",
"    </li>",
"    <li>",
"     Kaelin, C, Coltrera, F, Gardiner, J, Prouty, J. The Breast Cancer Survivor's Fitness, McGraw-Hill, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/20\">",
"      Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006; 7:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/21\">",
"      Blom Goldman U, Wennberg B, Svane G, et al. Reduction of radiation pneumonitis by V20-constraints in breast cancer. Radiat Oncol 2010; 5:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/22\">",
"      Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998; 16:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/23\">",
"      H&oslash;jris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999; 354:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/24\">",
"      Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/25\">",
"      Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/26\">",
"      Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/27\">",
"      Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008; 112:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/28\">",
"      Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 2008; 26:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/29\">",
"      Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003; 30:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/30\">",
"      Rubagotti A, Perrotta A, Casella C, Boccardo F. Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer. Ann Oncol 1996; 7:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/31\">",
"      Roychoudhuri R, Evans H, Robinson D, M&oslash;ller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004; 91:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/32\">",
"      Morton LM, Gilbert ES, Hall P, et al. Risk of treatment-related esophageal cancer among breast cancer survivors. Ann Oncol 2012; 23:3081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/33\">",
"      Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/34\">",
"      Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/35\">",
"      Linassier C, Barin C, Calais G, et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 2000; 11:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/36\">",
"      Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007; 25:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/37\">",
"      Fisher B, Rockette H, Fisher ER, et al. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol 1985; 3:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/38\">",
"      Kaplan HG, Malmgren JA, Atwood M. Leukemia incidence following primary breast carcinoma treatment. Cancer 2004; 101:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/39\">",
"      Howard RA, Gilbert ES, Chen BE, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat 2007; 105:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/40\">",
"      Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:4179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/41\">",
"      Wilking N, Lidbrink E, Wiklund T, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007; 18:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/42\">",
"      Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/43\">",
"      Beadle G, Baade P, Fritschi L. Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Ann Oncol 2009; 20:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/44\">",
"      Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park) 2001; 15:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/45\">",
"      Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 2012; 30:3578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/46\">",
"      Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005; 104:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/47\">",
"      Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005; 59:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/48\">",
"      Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006; 20:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/49\">",
"      Ferguson RJ, Ahles TA, Saykin AJ, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 2007; 16:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/50\">",
"      Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/51\">",
"      Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985; 55:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/52\">",
"      Siris ES, Leventhal BG, Vaitukaitis JL. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976; 294:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/53\">",
"      Bakri YN, Pedersen P, Nassar M. Normal pregnancy after curative multiagent chemotherapy for choriocarcinoma with brain metastases. Acta Obstet Gynecol Scand 1991; 70:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/54\">",
"      Kornblith AB, Herndon JE 2nd, Weiss RB, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer 2003; 98:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?8/0/8202/abstract/55\">",
"      Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 754 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B987512CC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8202=[""].join("\n");
var outline_f8_0_8202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32247236\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1203495\">",
"      OVERVIEW OF BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201175\">",
"      Treatment overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1201190\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1201197\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35822819\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35822834\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35822944\">",
"      Anti-HER2 directed treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELAPSE PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Locoregional recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1199208\">",
"      SECOND PRIMARY BREAST TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LONG-TERM ADVERSE EFFECTS OF PRIMARY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201318\">",
"      Chest wall and breast complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201327\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1202250\">",
"      Lymphedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201336\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201402\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1202380\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular morbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541709382\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541709389\">",
"      - Systemic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541709417\">",
"      - Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Second cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541709403\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541709410\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H556219388\">",
"      Cognitive dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Psychological effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541709437\">",
"      APPROACH TO THE LONG-TERM SURVIVOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32247236\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/754|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/58/16303\" title=\"table 1\">",
"      2002 TNM breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/53/26459\" title=\"table 2\">",
"      Signs symptoms breast CA recur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/44/4813\" title=\"table 3\">",
"      Common long-term and late effects of breast cancer treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30359?source=related_link\">",
"      Complications of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35466?source=related_link\">",
"      Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4292?source=related_link\">",
"      Role of breast surgery for stage IV breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_0_8203="Classif autoimmune hepatitis";
var content_f8_0_8203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of and autoantibodies in autoimmune hepatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Autoantibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        1 (classic)",
"       </td>",
"       <td>",
"        Antinuclear antibodies (ANA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-smooth muscle antibodies (ASMA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-actin antibodies (AAA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-soluble liver/liver pancreas antigen (anti-SLA/LP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical perinuclear antineutrophil cytoplasmic antibodies (pANCA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimitochondrial antibodies (AMA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        2",
"       </td>",
"       <td>",
"        Anti-liver/kidney microsomal-1 (anti-LKM-1) antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-liver cytosol-1 (anti-LC1) antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-SLA/LP",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8203=[""].join("\n");
var outline_f8_0_8203=null;
var title_f8_0_8204="Pulm drug complication II";
var content_f8_0_8204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary complications of cardiovascular drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Beta blockers",
"       </td>",
"       <td>",
"        Cough or bronchospasm",
"       </td>",
"       <td>",
"        Common; usually occurs in patients with asthma or COPD;&nbsp;&beta;1-selective agents, labetalol, esmolol, and pindolol are",
"better tolerated than nonselective agents",
"       </td>",
"       <td>",
"        Direct antagonism of &beta;2 receptor-mediated",
"bronchodilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary fibrosis",
"       </td>",
"       <td>",
"        Rare&nbsp;",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus-like syndrome",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydralazine",
"       </td>",
"       <td>",
"        Lupus-like syndrome",
"       </td>",
"       <td>",
"        Renal disease more common than in other drug-induced",
"lupus-like syndromes",
"       </td>",
"       <td>",
"        Unknown; slow acetylation may be a risk factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipyridamole (IV form only)",
"       </td>",
"       <td>",
"        Bronchospasm",
"       </td>",
"       <td>",
"        Occurs in about 0.15 percent of patients during",
"infusion for stress testing",
"       </td>",
"       <td>",
"        Induction of mast cell mediator release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Protamine",
"       </td>",
"       <td>",
"        Anaphylaxis, uritcaria, angioedema, bronchospasm",
"       </td>",
"       <td>",
"        Occurs in 0.2 percent of patients",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary hypertension",
"       </td>",
"       <td>",
"        Mild pulmonary hypertension and systemic hypotension in",
"up to 5 percent of patients; severe reaction rare",
"       </td>",
"       <td>",
"        Antiprotamine antibodies; activated neutrophils;",
"thromboxane A2 generation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Zitnik, RJ, J Respir Dis 1996; 17:254; and Zitnik, RJ, J Respir Dis 1996; 17:293.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8204=[""].join("\n");
var outline_f8_0_8204=null;
var title_f8_0_8205="Studies of ERCP complications";
var content_f8_0_8205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overall complications of endoscopic sphincterotomy and related mortality",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Author",
"       </td>",
"       <td>",
"        Cotton et al 1991",
"       </td>",
"       <td>",
"        Freeman et al 1996",
"       </td>",
"       <td>",
"        Rabenstein et al 1998",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Study",
"       </td>",
"       <td>",
"        Retrospective multicenter review",
"       </td>",
"       <td>",
"        Prospective multicenter study",
"       </td>",
"       <td>",
"        Prospective monocenter study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        7729",
"       </td>",
"       <td>",
"        2347",
"       </td>",
"       <td>",
"        746",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        234",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Perforation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Totals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        636",
"       </td>",
"       <td>",
"        229",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percent",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8205=[""].join("\n");
var outline_f8_0_8205=null;
var title_f8_0_8206="Contents: Melanocytic lesions and disorders of pigmentation";
var content_f8_0_8206=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Melanocytic lesions and disorders of pigmentation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Melanocytic lesions and disorders of pigmentation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Dermoscopy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/11/13497\">",
"           Dermoscopic evaluation of skin lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/57/38807\">",
"           Overview of dermoscopy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of pigmentation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/17/43287\">",
"           Benign pigmented skin lesions other than melanocytic nevi (moles)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/20/33092\">",
"           Melasma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/44/21193\">",
"           Vitiligo",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Melanocytic nevi",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/1/44056\">",
"           Acquired melanocytic nevi (moles)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/36/41545\">",
"           Atypical (dysplastic) nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/17/7447\">",
"           Congenital melanocytic nevi and speckled lentiginous nevi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/29/18906\">",
"           Spitzoid melanocytic neoplasms (Spitz nevus and atypical Spitz tumors)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Melanoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/60/37832\">",
"           Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/61/26585\">",
"           Initial surgical management of melanoma of the skin and unusual sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/52/10057\">",
"           Lentigo maligna: Clinical manifestations, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/8/2186\">",
"           Management of skin cancer in solid organ transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/31/22009\">",
"           Pathologic characteristics of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/11/1206\">",
"           Pathologic evaluation of regional lymph nodes in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/41/18073\">",
"           Primary prevention of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/53/24410\">",
"           Risk factors for the development of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/16/16650\">",
"           Screening and early detection of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/20/16713\">",
"           Skin examination and clinical features of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/15/35065\">",
"           Staging work-up and surveillance after treatment of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/31/42488\">",
"           Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-DE12972D3F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_0_8206=[""].join("\n");
var outline_f8_0_8206=null;
var title_f8_0_8207="Nasal allergen challenge";
var content_f8_0_8207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Responses to nasal allergen challenge",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 649px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Responses to allergen challenge. Time course of histamine release and physiologic changes after allergen challenge during the early phase response. The time course of histamine concentration, symptoms (sneezing) and increases in nasal airway resistance are closely correlated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baroody, FM, Naclerio, RM. Chapter 48. In: Second Edition Clinical Immunology Principles and Practice, Volume 1, Rich, RR, Fleisher, TA, Shearer, WT, et al (Eds), Mosby 2001. p.48.3. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_0_8207=[""].join("\n");
var outline_f8_0_8207=null;
